{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2020.10.27.20220871v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2020.10.27.20220871v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2020.10.27.20220871v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cp id=\u0022p-4\u0022\u003EWe assess the potential financial impact of future gene therapies by identifying the 109 late-stage gene therapy clinical trials currently underway, estimating the prevalence and incidence of their corresponding diseases, developing novel mathematical models of the increase in quality-adjusted life years for each approved gene therapy, and simulating the launch prices and the expected spending of these therapies over a 15-year time horizon. The results of our simulation suggest that an expected total of 1.09 million patients will be treated by gene therapy from January 2020 to December 2034. The expected peak annual spending on these therapies is $25.3 billion, and the total spending from January 2020 to December 2034 is $306 billion. We decompose their annual estimated spending by treated age group as a proxy for U.S. insurance type, and consider the tradeoffs of various methods of payment for these therapies to ensure patient access to their expected benefits.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E1 Introduction\u003C\/h2\u003E\u003Cp id=\u0022p-17\u0022\u003EGene therapy is a new class of medical treatment that alters part of a patient\u2019s genome through the replacement, deletion, or insertion of genetic material to treat a disease. While still in its infancy, gene therapy has demonstrated immense potential to treat and even cure previously intractable diseases. The introduction of voretigene neparvovec (marketed as Luxturna\u003Csup\u003E\u00ae\u003C\/sup\u003E) for inherited retinal disease and onasemnogene abeparvovec-xioi (marketed as Zolgensma\u003Csup\u003E\u00ae\u003C\/sup\u003E) for spinal muscular atrophy (SMA) in the U.S. have improved the lives of patients [\u003Ca id=\u0022xref-ref-115-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-115\u0022\u003E115\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-124-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-124\u0022\u003E124\u003C\/a\u003E]. Yet the price per treatment of $425,000 per eye for Luxturna, and $2.1 million per patient for Zolgensma, have raised concerns regarding affordability among budget-constrained payers and patients alike.\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EStakeholders have expressed concerns that gene therapy will be too expensive for individual patients to afford on their own, especially if they continue to be priced at more than 30 times the median household income of $61,937 [\u003Ca id=\u0022xref-ref-104-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-104\u0022\u003E104\u003C\/a\u003E], (equivalently, at several multiples of the average U.S. home mortgage of $354,400 [\u003Ca id=\u0022xref-ref-126-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-126\u0022\u003E126\u003C\/a\u003E]). Insurance coverage for gene therapy also varies by policy type. Many insurance policies do not cover access to gene therapy, or they impose very restrictive policies to limit the number of patients who might be treated [\u003Ca id=\u0022xref-ref-78-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-78\u0022\u003E78\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-156-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-156\u0022\u003E156\u003C\/a\u003E]. Widespread underinsurance in the U.S. [\u003Ca id=\u0022xref-ref-117-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-117\u0022\u003E117\u003C\/a\u003E]\u2014requiring substantial out-of-pocket costs in the form of deductibles and coinsurance payments\u2014may place gene therapy out of reach for American patients who might benefit from treatment. Many health plans, especially those facing fixed annual budgets, including state Medicaid policies, some employer-offered plans, and insurance offered on the federal and state-sponsored exchanges, have warned they may not be able or willing to absorb the additional spending should a greater number of people become eligible for expensive gene therapy once it reaches the market [\u003Ca id=\u0022xref-ref-159-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-159\u0022\u003E159\u003C\/a\u003E]. While some spending on novel gene therapies would likely be paid for by Medicare, the taxpayer-supported health insurance for Americans over the age of 65, other spending on these treatments might have an impact on the wages that private corporations pay to their employees [\u003Ca id=\u0022xref-ref-70-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-70\u0022\u003E70\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EIn this paper, we estimate the potential fiscal impact of gene therapy on the U.S. market. To do so, we create a new model to estimate the future number of gene therapy approvals, the size of their potential patient populations, and the prices of these future treatments. We begin by surveying the clinical trial databases for late-stage gene therapy trials, defined here as phase 2\/3 or phase 3, and compile the prevalence and incidence of the diseases targeted in these trials from a meta-analysis of published sources. We develop a novel method to estimate the price of each gene therapy under consideration by calculating the expected quality-adjusted life years gained for each therapy in the relevant patient population. Combining these results and previously published probabilities of technical success by therapeutic area, we simulate whether a disease will have an approved gene therapy over the next fifteen years, the expected number of treated patients and the expected spending from January 2020 to December 2034. Throughout this paper, the expected number of treated patients refers to the pool of eligible patients that remains after accounting for market penetration and the treatment schedule, explained in more detail in \u003Ca id=\u0022xref-sec-6-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-6\u0022\u003ESection 2.4\u003C\/a\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EOur results suggest that an estimated total of 1.09 million patients will be treated with gene therapy by the end of December 2034. The number of patients receiving gene therapies annually will peak at 94,696 patients in 2025 before declining to 65,612 at the end of our time period. The annual spending across all expected products and patients is expected to reach $25.3 billion in 2026. The cumulative spending on treating these patients in the 15-year period is estimated to be $306 billion, or $241 billion when discounted by 3% per annum to 2020 dollars. We decompose the expected spending by patient age group as a proxy for insurance type. For the expected spending on these therapies that is not covered by Medicare, we consider several alternate ways of financing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E2 Simulation Design\u003C\/h2\u003E\u003Cp id=\u0022p-21\u0022\u003EA critical element in our simulation analysis is the number of gene therapies that will receive regulatory approval over the next few years. Therefore, we begin with a brief review of the approval process in the U.S.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003ESince the passing of the Food, Drug, and Cosmetic Act in 1938, pharmaceuticals developed by companies have to be reviewed by the Food and Drug Administration (FDA) for safety and efficacy before they can be marketed in the U.S. The application for marketing approval differs slightly by the type of therapy: New Drug Applications (NDAs) are for small molecules, and Biologics License Applications (BLAs) are for biologics. Gene therapy is considered a biologic product, hence the BLA designation applies.\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EClinical investigations in human subjects typically take place in three phases\u2014phases 1, 2 and 3\u2014before marketing approvals are sought. Phase 1 trials are designed to investigate the dosage and safety of the treatment, while phase 2 trials attempt to detect early signs of efficacy and possible side effects in a relatively small sample of patients. Phase 3 trials are intended to demonstrate a statistically significant treatment effect when compared to the best standard of care in a broader population of patients. Some clinical trials combine multiple phases into a single design, with the phase numbers separated by a slash. For example, a phase 2\/3 trial combines elements of phase 2 and phase 3 investigations into a single trial design in order to reduce the overall development time and cost, and maximize the participation of subjects with orphan disease willing to participate in trials. The clinical development of therapeutics is a tedious and costly process that may span decades and cost billions of dollars, with the bulk of the cost and time spent conducting phase 3 clinical trials [\u003Ca id=\u0022xref-ref-63-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-63\u0022\u003E63\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-84-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-84\u0022\u003E84\u003C\/a\u003E]. The process is also very risky, with only 13.8% of therapeutic development programs entering phase 1 reaching approval [\u003Ca id=\u0022xref-ref-166-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-166\u0022\u003E166\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003ETo estimate the financial impact of gene therapies on the U.S. healthcare system, we first identify all existing late-stage clinical trials of gene therapies, simulate their successes or failures from phase 2\/3 or 3 to approval, then estimate the spending on the successful ones by summing the product of their expected prices and number of patients, as outlined in \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E. By using simulation analysis rather than purely deterministic methods, we are able to capture the inherent uncertainty in costs, revenues, and other parameters of this new therapeutic class.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022A flowchart showing the performance of the simulation. After extracting the information on each disease from the clinical trial databases, we simulate whether the disease will obtain an approval. If it fails to do so, the simulation will end for this disease in this iteration. Otherwise, we will estimate the expected number of patients to be treated, compute the corresponding cost of treatment, and store the results. At each step of the computation, we source data from literature and impute missing information.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;A flowchart showing the performance of the simulation. After extracting the information on each disease from the clinical trial databases, we simulate whether the disease will obtain an approval. If it fails to do so, the simulation will end for this disease in this iteration. Otherwise, we will estimate the expected number of patients to be treated, compute the corresponding cost of treatment, and store the results. At each step of the computation, we source data from literature and impute missing information.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022191\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022191\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1:\u003C\/span\u003E \u003Cp id=\u0022p-25\u0022 class=\u0022first-child\u0022\u003EA flowchart showing the performance of the simulation. After extracting the information on each disease from the clinical trial databases, we simulate whether the disease will obtain an approval. If it fails to do so, the simulation will end for this disease in this iteration. Otherwise, we will estimate the expected number of patients to be treated, compute the corresponding cost of treatment, and store the results. At each step of the computation, we source data from literature and impute missing information.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-26\u0022\u003EWe organize the simulation into the following five distinct modules, and describe each of these in some detail: (1) identifying the number of gene therapies currently in clinical trials; (2) estimating the probabilities of success of these trials; (3) estimating the time to approval; (4) simulating the expected number of patients treated by these therapies if approved; and (5) estimating the expected market prices of the approved therapies. We describe the first four modules in \u003Ca id=\u0022xref-sec-3-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-3\u0022\u003ESections 2.1\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-sec-6-2\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-6\u0022\u003E2.4\u003C\/a\u003E. Given the importance and potential controversies surrounding the pricing of gene therapies, we devote a standalone section to this issue in \u003Ca id=\u0022xref-sec-10-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-10\u0022\u003ESection 3\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.1 Clinical Trial Data\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003EWe use clinical trial metadata from the Citeline TrialTrove database and the U.S. National Library of Medicine\u2019s \u003Ca href=\u0022http:\/\/ClinicalTrials.gov\u0022\u003EClinicalTrials.gov\u003C\/a\u003E database to determine the number of gene therapies currently under development and their potential number of patients.\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003EWe download data from the Citeline database, isolating trials tagged with \u2018gene therapy\u2019 under the \u2018therapeutic class\u2019 field. We supplement this information by searching for trials on the \u003Cem\u003Eclinicaltrials\u003C\/em\u003E.\u003Cem\u003Egov\u003C\/em\u003E main page using the key words \u2018gene therapy\u2019, then reading the trial description to determine if the trial is in fact related to a gene therapy. All database queries were made before May 31, 2019. Clinical trials from both sources are merged before filtering for clinical trials that are in either phase 2\/3 or phase 3 of the development process and are not known to be compassionate uses of the treatment.\u003Csup\u003E\u003Ca id=\u0022xref-fn-3-1\u0022 class=\u0022xref-fn\u0022 href=\u0022#fn-3\u0022\u003E1\u003C\/a\u003E\u003C\/sup\u003E The outcomes of compassionate use are rarely used as data points in the clinical development process. Even though adverse events from compassionate use are reported to the FDA and may, in rare cases, be used to characterize the risk and benefits of a therapy, the FDA is cognizant that these uses often occur outside of clinical trial settings, and has almost never given an unfavorable decision to a product labeling because of an adverse outcome of compassionate use [\u003Ca id=\u0022xref-ref-88-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-88\u0022\u003E88\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-116-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-116\u0022\u003E116\u003C\/a\u003E]. We include clinical trials without U.S. trial site in our dataset because it is currently possible for the FDA, as empowered by Federal administrative law 21 CFR Part 312.120, to grant marketing approval using evidence from foreign clinical trials [\u003Ca id=\u0022xref-ref-68-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-68\u0022\u003E68\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EOur filtering criteria are intended to remove trial entries unrelated to the clinical development process, and to isolate gene therapies that are most likely to seek regulatory approval in the U.S. in the near future.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EWe remove repeated entries, and identify the diseases and therapeutic areas targeted by each gene therapy. Each clinical trial entry in our dataset contains a brief title of the trial, its clinical phase, the disease being targeted, the start and end dates of the clinical trial, the therapy name, and the companies involved in the clinical trial.\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EThis process yields 109 trials investigating 57 distinct diseases, listed in \u003Ca id=\u0022xref-table-wrap-11-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T11\u0022\u003ETable A1\u003C\/a\u003E in Supplementary Materials. We classify the diseases into three categories: cancer (oncology),\u003Csup\u003E\u003Ca id=\u0022xref-fn-4-1\u0022 class=\u0022xref-fn\u0022 href=\u0022#fn-4\u0022\u003E2\u003C\/a\u003E\u003C\/sup\u003E rare disease, and general disease. The distribution of disease and the clinical trials by category and therapeutic area are shown in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E and \u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E. The majority of trials and diseases are in the area of oncology, followed by rare diseases. These therapeutic areas are notoriously risky. Only 3.1% and 6.2% of the drug development programs in oncology and rare diseases go from Phase 1 to approval, respectively, compared to the baseline of 13.8% across all drugs and indications [\u003Ca id=\u0022xref-ref-166-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-166\u0022\u003E166\u003C\/a\u003E].\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125802\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125802\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125802\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1:\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECount of number of clinical trials by category and therapeutic area.\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125787\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125787\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125787\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2:\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECount of number of diseases by category and therapeutic area.\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.2 Probability of Success Estimates\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003EWe define a gene therapy development program as the set of clinical trials by a sponsor testing a therapeutic for a disease. We consider whether a gene therapy will be developed for a disease by simulating correlated coin flips\u2019 for each gene therapy program, and observing if there is at least one approval.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EOur computational method assumes that clinical trials are always perfectly correlated within the same development program. This is logical, since the FDA requires findings from at least two pivotal trials in the BLA review process[\u003Ca id=\u0022xref-ref-171-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-171\u0022\u003E171\u003C\/a\u003E]\u003Csup\u003E\u003Ca id=\u0022xref-fn-5-1\u0022 class=\u0022xref-fn\u0022 href=\u0022#fn-5\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E. Our assumption can also be justified for clinical trials run by the same sponsor that target the same disease, but for different patient segments. We reason that the sponsors are risking multiple expensive late-stage trials for the same disease, thus have confidence that the treatment will work on all patient sub-populations, and therefore any marketing licensing approval (or denial) will be similar for all the patient segments.\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003EIt can be argued that different gene therapy treatments for a disease are highly correlated, since they operate on similar platforms (e.g. CAR-T or in-vivo gene delivery using adeno-associated virus vectors), even though different gene sequences may be targeted. To reflect this, we consider a correlation of 90% between development programs in our simulations. Our sensitivity analysis, however, demonstrates that these computations are insensitive to this parameter (see \u003Ca id=\u0022xref-sec-17-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-17\u0022\u003ESection 4.3\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-35\u0022\u003EThe phase 3 to approval probability of success (PoS\u003Csub\u003E3\u003Cem\u003EA\u003C\/em\u003E\u003C\/sub\u003E) for each disease is informed by prior studies on the probabilities of success of drug development programs by therapeutic area from the MIT Laboratory of Financial Engineering\u2019s Project ALPHA website [\u003Ca id=\u0022xref-ref-97-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-97\u0022\u003E97\u003C\/a\u003E]. These estimates for the probabilities of success are derived from over 55,000 drug development programs between January 2000 and January 2020, and computed using the path-by-path methods as introduced in Wong et al. [\u003Ca id=\u0022xref-ref-166-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-166\u0022\u003E166\u003C\/a\u003E]. The PoS\u003Csub\u003E3\u003Cem\u003EA\u003C\/em\u003E\u003C\/sub\u003E values used in our simulations are given in \u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E and the mapping of diseases to therapeutic areas is shown in \u003Ca id=\u0022xref-table-wrap-12-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T12\u0022\u003ETable A2\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125798\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125798\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125798\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3:\u003C\/span\u003E \u003Cp id=\u0022p-36\u0022 class=\u0022first-child\u0022\u003EThe probability of success of drug development programs from phase 3 to approval (PoS\u003Csub\u003E3\u003Cem\u003EA\u003C\/em\u003E\u003C\/sub\u003E), categorized by therapeutic area. We assume that the probability of success for gene therapy follows a similar pattern.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.3 Time to Approval\u003C\/h3\u003E\u003Cp id=\u0022p-37\u0022\u003EWe also require an estimate of the time to approval for gene therapy treatments in order to assess the patient impact and cost over time. Typically, companies submit their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) some time after the end of the clinical trial period. We assume that the time between the end of the last clinical trial for the disease and the submission of the BLA is a variable drawn from a triangular distribution between 0 and 365 days, with a median of 182.5 days. This is informed by the practical knowledge that it takes an average of 6 months to prepare the documents for the BLA submission [\u003Ca id=\u0022xref-ref-166-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-166\u0022\u003E166\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EIn addition, there will be a lag time between the submission of the BLA and the decision of the FDA. The FDA has 60 days to decide if it will follow up on a BLA filing [\u003Ca id=\u0022xref-ref-91-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-91\u0022\u003E91\u003C\/a\u003E], and it can take another 10 months to deliver its verdict [\u003Ca id=\u0022xref-ref-90-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-90\u0022\u003E90\u003C\/a\u003E]. This implies the maximum possible time between BLA submission and FDA approval will be 12 months. We thus assume that the time between the BLA submission and the FDA decision is drawn from a triangular distribution between 0 and 365 days, with a median of 182.5 days. Our assumptions are also valid for therapies that use the priority review pathways.\u003C\/p\u003E\u003Cp id=\u0022p-39\u0022\u003EWe also assume that the BLA will be filed only after the last clinical trial for a disease has ended. Trials with missing declared end dates will have their end dates imputed by adding random durations to the trial start date, drawn from a gamma distribution fitted to clinical trials with complete date information in our data (see \u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022The empirical distribution of duration against our fitted gamma distribution. \u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;The empirical distribution of duration against our fitted gamma distribution.\u0026lt;\/span\u0026gt; \u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022197\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022197\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2:\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EThe empirical distribution of duration against our fitted gamma distribution.\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-40\u0022\u003EDiseases with a prior approved therapy will automatically be considered to be approved as of January 1st 2020. For some diseases, the last clinical trial will have ended more than three years ago (i.e., before January 2017). For diseases that match this criterion, we treat them as though they have failed.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.4 Number of Patients\u003C\/h3\u003E\u003Cp id=\u0022p-41\u0022\u003EThe second module simulates the number of new and existing patients that will be treated over time, conditioned on the disease receiving an approved gene therapy.\u003C\/p\u003E\u003Cp id=\u0022p-42\u0022\u003EWe consider only the superset of the patient segments listed in the clinical trials for each disease. For example, if there are two clinical trials, one targeting \u2018patients above the age of 40\u2019 and the other targeting \u2018patients above the age of 18\u2019, we only consider the latter when estimating the patient population for the disease. If insufficient information about the sub-population is given, we assume that all the patients with that disease are eligible. The proportion of patients who are eligible for treatment and are willing to do so will be taken into account later, as we will explain in \u003Ca id=\u0022xref-sec-6-3\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-6\u0022\u003ESection 2.4\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EIncidence and Prevalence\u003C\/h4\u003E\u003Cp id=\u0022p-43\u0022\u003EFor the number of currently affected patients and the number of new patients per year for each indication, we source medical journals and online data repositories, such as the Surveillance, Epidemiology, and End Results (SEER) website and \u003Cem\u003Ecancer\u003C\/em\u003E.\u003Cem\u003Enet\u003C\/em\u003E. If we are able to find an estimated patient population, we cite it directly. Otherwise, we multiply the prevalence and incidence rates by the population of the U.S., which we take to be 327.7 million [\u003Ca id=\u0022xref-ref-74-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-74\u0022\u003E74\u003C\/a\u003E]. When necessary, we also make the assumption that the female to male ratio is 1:1.\u003C\/p\u003E\u003Cp id=\u0022p-44\u0022\u003EIn cases in which we are able to find estimates for the disease incidence but not the prevalence, we combine the incidence of the disease (i.e., \u003Cem\u003Ei\u003C\/em\u003E new patients a year) and the disease survival rate (i.e., \u003Cem\u003Ep\u003C\/em\u003E% of the people with a disease will be alive after \u003Cem\u003Ek\u003C\/em\u003E years) to obtain the steady-state estimate of the prevalence (\u003Cem\u003Ej\u003C\/em\u003E) using Equation \u003Ca id=\u0022xref-disp-formula-1-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-1\u0022\u003EEquation 1\u003C\/a\u003E. The incidence can also be estimate from the prevalence by rearranging Equation \u003Ca id=\u0022xref-disp-formula-1-2\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-1\u0022\u003EEquation 1\u003C\/a\u003E to yield \u003Ca id=\u0022xref-disp-formula-2-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-2\u0022\u003EEquation 2\u003C\/a\u003E.\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-6.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-6.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-2\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-7.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-7.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nThe equations can be derived by assuming that the number of patients will be constant through the years at a level \u003Cem\u003Ej\u003C\/em\u003E. Since \u003Cem\u003Eki\u003C\/em\u003E new patients are added over \u003Cem\u003Ek\u003C\/em\u003E years and \u003Cem\u003Ej\u003C\/em\u003E(1 \u2212 \u003Cem\u003Ep\u003C\/em\u003E) patients that will die over the same period, \u003Cem\u003Eki\u003C\/em\u003E = \u003Cem\u003Ej\u003C\/em\u003E(1 \u2212 \u003Cem\u003Ep\u003C\/em\u003E) for the number of patients to be constant over time. Rearranging this equation will yield \u003Ca id=\u0022xref-disp-formula-1-3\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-1\u0022\u003EEquation 1\u003C\/a\u003E and \u003Ca id=\u0022xref-disp-formula-2-2\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-2\u0022\u003EEquation 2\u003C\/a\u003E. The number of patients for each disease are presented in \u003Ca id=\u0022xref-table-wrap-13-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T13\u0022\u003ETable A3\u003C\/a\u003E in the appendix. We adjust these estimates to avoid double-counting in cases of overlapping patient populations, e.g., the number of patients for \u2018Spinal Muscular Atrophy\u2019 is the difference between \u2018Spinal Muscular Atrophy\u2019 and \u2018Spinal Muscular Atrophy I\u2019 (a sub-category of the former).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003ETreatment of Patients over Time\u003C\/h4\u003E\u003Cp id=\u0022p-45\u0022\u003EIn our simulation, we assume that newly diagnosed patients are treated immediately upon diagnosis. We further assume that the proportion of existing patients who seek treatment do so in such a way that the existing stock of patient declines exponentially, with a half-life of \u003Cem\u003E\u03bb\u003C\/em\u003E. Mathematically, the proportion of existing patients that seek treatment between time \u003Cem\u003Et\u003C\/em\u003E and \u003Cem\u003Et\u003C\/em\u003E + \u003Cem\u003Ed\u003C\/em\u003E after approval is given by \u003Cem\u003EE\u003C\/em\u003E(\u003Cem\u003Et, d, \u03bb\u003C\/em\u003E), where:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-3\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-8.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-8.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nIn the face of limited information, we assume that 25% of the existing stock of patients will seek treatment in the first year of our simulation. This requires that the half-life be set to 28.91 months, which in turn implies that 95% of all patients who are diagnosed prior to the approval of the gene therapy want treatments within 10.5 years. Admittedly, this is just an assumption, and we perform a sensitivity analysis to determine its impact on our results in \u003Ca id=\u0022xref-sec-17-2\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-17\u0022\u003ESection 4.3\u003C\/a\u003E. Not everyone who seeks treatment will be given one; the effective number of patients treated is determined by the patient penetration rate, as we shall describe next.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EPatient Penetration\u003C\/h4\u003E\u003Cp id=\u0022p-46\u0022\u003EIt is unlikely that all the patients under consideration will receive gene therapy treatments. This may be due to ineligibility, lack of awareness of the treatment, or simply lack of interest in gene therapy, among many other reasons. We term the percentage of the patients that receive gene therapy treatments the \u2018patient penetration rate\u2019, and model it using a ramp function, \u003Cem\u003E\u03c1\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E, \u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E, \u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E). The ramp function is frequently used by the industry to model the rate of adoption of a product or technology [\u003Ca id=\u0022xref-ref-142-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-142\u0022\u003E142\u003C\/a\u003E], and is given by:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-4\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-9.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-9.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nAn illustration of the ramp function is given in \u003Ca id=\u0022xref-fig-3-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFigure 3\u003C\/a\u003E. \u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E and \u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E are assumed to follow Gaussian distributions \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-2\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-2.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-2.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E, respectively. The parameter settings are listed in \u003Ca id=\u0022xref-table-wrap-4-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETables 4\u003C\/a\u003E and \u003Ca id=\u0022xref-table-wrap-5-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T5\u0022\u003E5\u003C\/a\u003E. When setting \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003E\u03b8\u003C\/em\u003E\u003C\/sub\u003E and \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ET\u003C\/em\u003E\u003C\/sub\u003E, we need to take into the account the nature of the diseases. At one extreme, we have rare diseases, which are often life-threatening, and affect a relatively small number of people. Faced with these prospects of survival, more patients are willing to enroll in new treatments quickly after they are approved. In addition, since the number of patients is relatively small, insurers are more willing to cover these therapies and manufacturers are more able to cope with a larger proportion of patients. Given this, we assign a high value of 40% for \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003E\u03b8\u003C\/em\u003E\u003C\/sub\u003E, and a low value of 6 months for \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ET\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T4\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125812\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125812\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125812\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 4:\u003C\/span\u003E \u003Cp id=\u0022p-47\u0022 class=\u0022first-child\u0022\u003EParameter settings for \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-3\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T4\/embed\/inline-graphic-3.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T4\/embed\/inline-graphic-3.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T5\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125789\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125789\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125789\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 5:\u003C\/span\u003E \u003Cp id=\u0022p-48\u0022 class=\u0022first-child\u0022\u003EParameter settings for \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-4\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T5\/embed\/inline-graphic-4.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T5\/embed\/inline-graphic-4.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E. We consider the severity of the disease and the number of patients when making the assumptions.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F3\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F3.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022An illustration of the ramp function used to model the patient penetration rate over time.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;An illustration of the ramp function used to model the patient penetration rate over time.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 3:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022374\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 3:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022374\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F3.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 3:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F3.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 3:\u003C\/span\u003E \u003Cp id=\u0022p-49\u0022 class=\u0022first-child\u0022\u003EAn illustration of the ramp function used to model the patient penetration rate over time.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-50\u0022\u003EOn the other hand, general diseases are seldom deadly, and affect a large number of patients, possibly even in the millions. Since an acceptable standard of care is available for these conditions, patients may be less inclined to use new treatments due to fear of the unfamiliar. In addition, it is often financially difficult for insurance companies to cover so many patients. We thus assume that the maximum penetration rate will be 1%, and the ramp-up period, 5 years.\u003C\/p\u003E\u003Cp id=\u0022p-51\u0022\u003EAs an intermediate case, cancers have characteristics that fall between these two extremes, but in general, they are more similar to rare diseases. We therefore assign values of 10% and 12 months to the maximum penetration rate and ramp-up period, respectively. All variances are set to 10% of the means to model moderate uncertainty in our numbers. They do not affect our mean estimates of the number of impacted patients or spending on gene therapy.\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003EThe net number of patients to be treated for the disease at time \u003Cem\u003Et\u003C\/em\u003E after the approval of a gene therapy is given by:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-5\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-13.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-13.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nWe do not consider the effect of market competition among different therapies for the same disease and patient groups on the number of treated patients. In our model, there is only one approval per disease, and a fraction of the eligible patients will receive that treatment.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-10\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E3 Pricing\u003C\/h2\u003E\u003Cp id=\u0022p-53\u0022\u003EThe cost to the healthcare system of providing the gene therapy for a disease for all patients being treated at time \u003Cem\u003Et\u003C\/em\u003E after approval is given by \u003Cem\u003EC\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E), where\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-6\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-14.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-14.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nThe price of each treatment is crucial to computing the expected total spending, and a source of considerable controversy because of the high price of gene therapies relative to many conventional therapeutics. The Institute for Clinical and Economic Review (ICER)\u2014 an independent nonprofit organization that aims to evaluate the clinical and economic value of healthcare innovation\u2014has advocated pricing drugs and gene therapies by the relative risk and benefit to the patient. This is typically done by comparing the quality-adjusted life years (QALY) with and without the treatment, then multiplying the change in QALY (\u0394QALY) by a constant, typically set between $50,000 and $150,000 per \u0394QALY [\u003Ca id=\u0022xref-ref-135-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-135\u0022\u003E135\u003C\/a\u003E].\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-7\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-15.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-15.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nICER has published reports containing its estimates of QALY gained by patients with vision loss associated with biallelic RPE65-mediated retinal disease following treatment with Luxturna\u003Csup\u003E\u00ae\u003C\/sup\u003E [\u003Ca id=\u0022xref-ref-124-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-124\u0022\u003E124\u003C\/a\u003E], and with SMA Type I following treatment with Zolgensma\u003Csup\u003E\u00ae\u003C\/sup\u003E [\u003Ca id=\u0022xref-ref-82-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-82\u0022\u003E82\u003C\/a\u003E]. These reports compute \u0394QALY using the results of clinical trials to make informed estimates about the potential improvements in the quality of life and life expectancy of the patients.\u003C\/p\u003E\u003Cp id=\u0022p-54\u0022\u003EWhile ICER\u2019s methods are considered by some stakeholders to be the gold standard for this type of calculation, replicating its methods for all the clinical trials under consideration is not feasible in this paper, given the fact that all the clinical trials in our analysis are still pending. As an alternative, we develop a mathematical model to estimate the expected increase in QALY for each disease in our sample.\u003C\/p\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.1 Estimating \u0394QALY\u003C\/h3\u003E\u003Cp id=\u0022p-55\u0022\u003EWe consider a representative patient who is expected to live to the age of \u003Cem\u003Ex\u003C\/em\u003E with a probability of \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E). The function \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E) is also known as the survival curve of the population. The patient enjoys a quality of life, \u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es, x\u003C\/em\u003E), that is dependent on his age, \u003Cem\u003Ex\u003C\/em\u003E, and his state of health, \u003Cem\u003Es\u003C\/em\u003E. The expected QALY of a typical person in the baseline state of \u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (the \u2018healthy\u2019 state) can be computed by integrating \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E)\u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, \u003Cem\u003Ex\u003C\/em\u003E) over \u003Cem\u003Ex\u003C\/em\u003E.\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-8\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-16.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-16.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nSuppose that the patient is afflicted with a disease at time \u003Cem\u003Ea\u003C\/em\u003E, which changes his survival curve after time \u003Cem\u003Ea\u003C\/em\u003E from \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E) to \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-5\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-5.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-5.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E. Likewise, his quality of life after diagnosis changes from \u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, \u003Cem\u003Ex\u003C\/em\u003E) to \u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ed\u003C\/em\u003E\u003C\/sub\u003E, \u003Cem\u003Ex\u003C\/em\u003E). This patient will then have an expected QALY of:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-9\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-17.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-17.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nThe change in the expected QALY due to the disease can then be expressed as:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-10\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-18.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-18.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-11\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-19.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-19.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-12\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-20.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-20.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-13\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-21.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-21.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nIt is customary in the literature to incorporate time preferences into the model. This is done by multiplying the integrand by the discount factor, \u003Cem\u003Er\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E). There is a normalization term \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ea\u003C\/em\u003E) to reflect conditional survival to age \u003Cem\u003Ex\u003C\/em\u003E.\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-14\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-22.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-22.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nIf the distribution of age when the patient population contracts the disease is given by \u003Cem\u003EA\u003C\/em\u003E(\u003Cem\u003Ea\u003C\/em\u003E), then the expected decrease in QALY over the patient population is given by:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-15\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-23.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-23.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003Ca id=\u0022xref-disp-formula-15-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-15\u0022\u003EEquation 15\u003C\/a\u003E is a general formula that accounts for the expected value of the changes in QALY between two states of health using only three variables: the time of disease onset, and the utility of the two health states. By making the relevant substitutions, we can also apply this formula to compute the expected changes in QALY given a gene therapy (\u003Cem\u003Egt\u003C\/em\u003E) and an alternative treatment (\u003Cem\u003Ealt\u003C\/em\u003E).\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-16\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-24.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-24.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nWhile death and patient statistics can be collected to determine \u003Cem\u003El\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E) and \u003Cem\u003EA\u003C\/em\u003E(\u003Cem\u003Ea\u003C\/em\u003E) empirically, determining \u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es, x\u003C\/em\u003E) and \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-6\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-6.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-6.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E is challenging. Therefore, we use simple functions to modify these variables. In particular, we assume that being afflicted with a severe disease will modify the survival curve by a multiplicative factor, \u003Cem\u003ED\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E). That is, the survival curve of a patient after he is diagnosed at age \u003Cem\u003Ea\u003C\/em\u003E is given by:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-17\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-25.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-25.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nThis functional form assumes that the disease is age-agnostic, and affects the survival curve only through the time elapsed since the patient has been diagnosed. For example, if the disease does not affect mortality (e.g. blindness), then \u003Cem\u003ED\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E) = 1 for all \u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea \u0026gt;\u003C\/em\u003E 0. On the other hand, if the condition causes death immediately, then \u003Cem\u003ED\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E) = 0 for all \u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea \u0026gt;\u003C\/em\u003E 0.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003EFor the utility function, \u003Cem\u003Ef\u003C\/em\u003E (\u003Cem\u003Es, x\u003C\/em\u003E), we assume that it can be decomposed into two multiplicative factors, one dependent only on age, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ea\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E), and the other dependent only on the state of health, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E):\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-18\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-26.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-26.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nAssuming that \u003Ca id=\u0022xref-disp-formula-17-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-17\u0022\u003EEquations 17\u003C\/a\u003E and \u003Ca id=\u0022xref-disp-formula-18-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-18\u0022\u003E18\u003C\/a\u003E hold, \u003Ca id=\u0022xref-disp-formula-16-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-16\u0022\u003EEquation 16\u003C\/a\u003E can be simplified to:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-19\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-27.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-27.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nwhere \u003Cem\u003EK\u003C\/em\u003E(\u003Cem\u003Ex, a\u003C\/em\u003E) is the change in the quality-adjusted life years:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-20\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-28.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-28.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\n\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.2 Calibration of \u0394QALY\u003C\/h3\u003E\u003Cp id=\u0022p-57\u0022\u003EFor each of these variables, we attempt to obtain empirical values from the literature as much as possible. When necessary, we interpolate values, briefly explaining our assumptions and the data collection methods for the inputs to the model.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003EFor the age-dependent QoL, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ea\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E), we extract the general population utility values from Institute for Clinical and Economic Review [\u003Ca id=\u0022xref-ref-115-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-115\u0022\u003E115\u003C\/a\u003E] and fit a linear model across the data. The QoL values and the fitted model are shown in \u003Ca id=\u0022xref-fig-4-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022F4\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F4.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Age-dependent QoL, fa(x). The values extracted from ICER\u0026#x2019;s SMA final report [115] are replicated in the table on the left and are presented as crosses in the figure on the right. A linear line, with its intercept set to 1, is fitted with the data points.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Age-dependent QoL, \u0026lt;em\u0026gt;f\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;a\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;(\u0026lt;em\u0026gt;x\u0026lt;\/em\u0026gt;). The values extracted from ICER\u0026#x2019;s SMA final report [115] are replicated in the table on the left and are presented as crosses in the figure on the right. A linear line, with its intercept set to 1, is fitted with the data points.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 4:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022151\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 4:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022151\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F4.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 4:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F4.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 4:\u003C\/span\u003E \u003Cp id=\u0022p-59\u0022 class=\u0022first-child\u0022\u003EAge-dependent QoL, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ea\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E). The values extracted from ICER\u2019s SMA final report [\u003Ca id=\u0022xref-ref-115-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-115\u0022\u003E115\u003C\/a\u003E] are replicated in the table on the left and are presented as crosses in the figure on the right. A linear line, with its intercept set to 1, is fitted with the data points.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-60\u0022\u003ESince we are unable to know the patient outcomes for these potential gene therapies ahead of their approval, we assume that the gene therapy treatments will restore a person\u2019s survivability to that of a normal individual. This implies that \u003Cem\u003ED\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Egt\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E) = 1. To estimate the impact of a disease on patient survivability, we model its survival curve, \u003Cem\u003ED\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E), using the exponential survival curve shown in \u003Ca id=\u0022xref-disp-formula-21-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-21\u0022\u003EEquation 21\u003C\/a\u003E. In the equation, \u003Cem\u003E\u03bb\u003C\/em\u003E is the force of mortality, and \u003Cem\u003E\u03bc\u003C\/em\u003E is the normalization factor. We estimate \u003Cem\u003E\u03bb\u003C\/em\u003E and \u003Cem\u003E\u03bc\u003C\/em\u003E by matching the function to \u003Cem\u003ET\u003C\/em\u003E -year survival rates, which are the proportions of the patients (\u003Cem\u003Ek\u003C\/em\u003E) who will be alive after \u003Cem\u003ET\u003C\/em\u003E years, from data. The parameter values and their sources are listed in \u003Ca id=\u0022xref-table-wrap-14-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T14\u0022\u003ETable A4\u003C\/a\u003E in the Supplementary Material.\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-21\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-30.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-30.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nThe health-related quality of life variables, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Egt\u003C\/em\u003E\u003C\/sub\u003E) \u0026amp; \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E), are treated separately, depending on the disease classification. For cancerous indications, we assume that the quality of life of the patients is not affected by the disease. For non-cancerous indications, we source the medical literature for the available quality of life (QoL) estimates. We use the QoL for the typical disease condition to approximate the \u2018before treatment\u2019 QoL, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E), and use the best possible outcome for each condition as the \u2018post-treatment\u2019 QoL, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Egt\u003C\/em\u003E\u003C\/sub\u003E). We interpolate the missing values using linear regressions of the sourced QoLs against disease severity. To do this, we first give scores, \u003Cem\u003E\u03b6\u003C\/em\u003E, ranging from one to five for each disease, based on our perception of disease severity. We then fit a line of \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E) against \u003Cem\u003E\u03b6\u003C\/em\u003E in order to estimate the missing \u2018before treatment\u2019 QoL values, \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E) (see \u003Ca id=\u0022xref-fig-5-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F5\u0022\u003EFigure 5\u003C\/a\u003E). We define \u0394QoL = \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Egt\u003C\/em\u003E\u003C\/sub\u003E) \u2212 \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E). Separately, we regress \u0394QoL against \u003Cem\u003E\u03b6\u003C\/em\u003E to interpolate the change in QoL (see \u003Ca id=\u0022xref-fig-6-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F6\u0022\u003EFigure 6\u003C\/a\u003E). Given \u0394QoL and \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E), we can then estimate the missing values of \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Egt\u003C\/em\u003E\u003C\/sub\u003E). Our estimated values are reported in \u003Ca id=\u0022xref-table-wrap-15-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T15\u0022\u003ETable A5\u003C\/a\u003E in the Supplementary Material.\u003C\/p\u003E\u003Cdiv id=\u0022F5\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F5.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Scatter plot of fh(salt) against disease score (\u0026#x3B6;)\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Scatter plot of \u0026lt;em\u0026gt;f\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;h\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;(\u0026lt;em\u0026gt;s\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;alt\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;) against disease score (\u0026lt;em\u0026gt;\u0026#x3B6;\u0026lt;\/em\u0026gt;)\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 5:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022189\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 5:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022189\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F5.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 5:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F5.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 5:\u003C\/span\u003E \u003Cp id=\u0022p-61\u0022 class=\u0022first-child\u0022\u003EScatter plot of \u003Cem\u003Ef\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eh\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E) against disease score (\u003Cem\u003E\u03b6\u003C\/em\u003E)\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F6\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F6.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Scatter plot of \u0026#x394;QoL against disease score (\u0026#x3B6;)\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Scatter plot of \u0026#x394;QoL against disease score (\u0026lt;em\u0026gt;\u0026#x3B6;\u0026lt;\/em\u0026gt;)\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 6:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F6.medium.gif\u0022 width=\u0022440\u0022 height=\u0022190\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 6:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F6.medium.gif\u0022 width=\u0022440\u0022 height=\u0022190\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F6.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 6:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F6.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 6:\u003C\/span\u003E \u003Cp id=\u0022p-62\u0022 class=\u0022first-child\u0022\u003EScatter plot of \u0394QoL against disease score (\u003Cem\u003E\u03b6\u003C\/em\u003E)\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-63\u0022\u003EWe are able to extract the distribution of the age of cancer onset from the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) Program website. However, empirical age distributions are practically nonexistent for non-cancerous diseases. To overcome this lack, we search the literature for the average age of diagnosis of each disease, and fit a triangle distribution for each disease using the optimization program shown in \u003Ca id=\u0022xref-fig-7-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F7\u0022\u003EFigure 7\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022F7\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F7.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022An optimization program to obtain the triangle distribution given the average age of diagnosis, \u0026#x3BC;age. xmin and xmax are coordinates of the base of the triangle. c and z are the mode and height of triangle.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;An optimization program to obtain the triangle distribution given the average age of diagnosis, \u0026lt;em\u0026gt;\u0026#x3BC;\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;age\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;. \u0026lt;em\u0026gt;x\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;min\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; and \u0026lt;em\u0026gt;x\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;max\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; are coordinates of the base of the triangle. \u0026lt;em\u0026gt;c\u0026lt;\/em\u0026gt; and \u0026lt;em\u0026gt;z\u0026lt;\/em\u0026gt; are the mode and height of triangle.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 7:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F7.medium.gif\u0022 width=\u0022440\u0022 height=\u0022168\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 7:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F7.medium.gif\u0022 width=\u0022440\u0022 height=\u0022168\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F7.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 7:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F7.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 7:\u003C\/span\u003E \u003Cp id=\u0022p-64\u0022 class=\u0022first-child\u0022\u003EAn optimization program to obtain the triangle distribution given the average age of diagnosis, \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eage\u003C\/em\u003E\u003C\/sub\u003E. \u003Cem\u003Ex\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emin\u003C\/em\u003E\u003C\/sub\u003E and \u003Cem\u003Ex\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E are coordinates of the base of the triangle. \u003Cem\u003Ec\u003C\/em\u003E and \u003Cem\u003Ez\u003C\/em\u003E are the mode and height of triangle.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-65\u0022\u003EThis program maximizes the domain\u2019s interval (Equation 22) while imposing the requirement that the distribution\u2019s mode, \u003Cem\u003Ec\u003C\/em\u003E, has to be in the domain (Equation 23). In addition, the area under the curve has to be equal to 1 (Equation 24), and the mean of the distribution has to be equal to the average age (Equation 25).\u003C\/p\u003E\u003Cp id=\u0022p-66\u0022\u003EWe experimented with an impulse function and an uniform distribution to model the age distribution, but these functions created unrealistic scenarios. Modeling the age distribution with the impulse function, while simple, will force \u003Ca id=\u0022xref-disp-formula-15-2\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-15\u0022\u003EEquation 15\u003C\/a\u003E to collapse into a single point, and lose any nuance in the QALY gained by patients of different ages. On the other hand, estimating a uniform distribution from the average age creates distributions with narrow support. The distributions from our optimization program have a wider base of support and avoid sharp changes in density. We illustrate this with some examples in \u003Ca id=\u0022xref-fig-14-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F14\u0022\u003EFigure A1\u003C\/a\u003E in the Supplementary Materials.\u003C\/p\u003E\u003Cp id=\u0022p-67\u0022\u003EWe assume a 3% per annum discount rate, as suggested by ICER for high-impact single or short-term therapy (SST) [\u003Ca id=\u0022xref-ref-92-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-92\u0022\u003E92\u003C\/a\u003E].\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.3 Price per \u0394QALY\u003C\/h3\u003E\u003Cp id=\u0022p-68\u0022\u003ETo estimate as realistic a market price of gene therapy as possible, we calibrate our assumed price per \u0394QALY with the 4 data points currently available: Zolgensma, priced at $2.1 million per patient [\u003Ca id=\u0022xref-ref-132-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-132\u0022\u003E132\u003C\/a\u003E], Luxturna, priced at $0.425 million per eye treated [\u003Ca id=\u0022xref-ref-157-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-157\u0022\u003E157\u003C\/a\u003E], Kymriah, priced at $0.475 million for a one-time dose [\u003Ca id=\u0022xref-ref-67-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-67\u0022\u003E67\u003C\/a\u003E], and Yescarta, priced at $0.373 million for a one-time dose [\u003Ca id=\u0022xref-ref-67-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-67\u0022\u003E67\u003C\/a\u003E]. Separately, Zynteglo, sold at a cost of 1.6 million Euros (approximately $1.8 million), has been approved in the European Union. The data points are listed in \u003Ca id=\u0022xref-table-wrap-6-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T6\u0022\u003ETable 6\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T6\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125780\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125780\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125780\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 6:\u003C\/span\u003E \u003Cp id=\u0022p-69\u0022 class=\u0022first-child\u0022\u003EDiseases under consideration, approved gene therapy treatments used as proxy, prices of approved treatments, countries\/areas in which treatments have been approved, and computed expected change in QALY.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-70\u0022\u003EWe calibrate the price per \u0394QALY by minimizing the mean-squared error (MSE) between the estimated price given the expected change in QALY and the actual price. We report the mean absolute percentage error (MAPE) between the estimated price and the actual price in addition to the MSE. We note that Zolgensma, Zynteglo, and Luxturna are gene replacement therapies for rare diseases, while Kymriah and Yescarta are chimeric antigen receptor T-cell (CAR-T) therapies indicated for cancers. As such, we perform two separate calibrations, one for rare diseases and the other for cancerous indications. We assume that the price per \u0394QALY for general diseases is identical to that for cancerous indications.\u003C\/p\u003E\u003Cp id=\u0022p-71\u0022\u003EConsidering only the therapies approved in the United States, we estimate a price per E(\u0394QALY) of $101,663 (MSE: 2.18\u003Cem\u003E\u00d7\u003C\/em\u003E10\u003Csup\u003E9\u003C\/sup\u003E, MAPE: 11.2%) for rare diseases and $40,797 (MSE: 1.77\u003Cem\u003E\u00d7\u003C\/em\u003E10\u003Csup\u003E1\u003C\/sup\u003E0, MAPE: 44.2%) for other diseases. Using all the data points, the price per E(\u0394QALY) for rare diseases increases to $114,781 (MSE: 1.70\u003Cem\u003E\u00d7\u003C\/em\u003E10\u003Csup\u003E12\u003C\/sup\u003E, MAPE: 108%). In this paper, we use the former for our calculations since it has a smaller mean-squared error and better reflects prices in the U.S., our focus. This value will give us estimates of $2.09M per patient for Zolgensma and $0.470M per eye for Luxturna.\u003C\/p\u003E\u003Cp id=\u0022p-72\u0022\u003EOur calibrated price per E(\u0394QALY) for cancerous indications is just slightly below ICER\u2019s $50,000 to $100,000 range for \u2018intermediate care value\u2019. The higher price per E(\u0394QALY) for rare diseases also reaffirms the general belief that developers of treatments for rare diseases should be compensated more for their elevated R\u0026amp;D risk and the low financial prospects of serving a small population of patients. It is assumed that the clinical cost of delivering the gene therapy is a negligible fraction of the overall cost of development (though they are considerably higher than the delivery cost of conventional therapeutics). It is also highly likely that the outside option cost will be similar.\u003C\/p\u003E\u003Cp id=\u0022p-73\u0022\u003EThe expected increases in QALY computed by our model are close to those provided by the ICER reports for the treatments [\u003Ca id=\u0022xref-ref-115-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-115\u0022\u003E115\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-124-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-124\u0022\u003E124\u003C\/a\u003E]. For example, we estimate that treatments for Spinal Muscular Atrophy Type 1 and Leber Congenital Amaurosis due to RPE65 Mutations provide 20.56 and 4.63 incremental QALYs, whereas ICER estimates Zolgensma and Luxturna to provide 12.23 to 26.58 and 1.3 to 2.7 incremental QALYs\u003Csup\u003E\u003Ca id=\u0022xref-fn-6-1\u0022 class=\u0022xref-fn\u0022 href=\u0022#fn-6\u0022\u003E4\u003C\/a\u003E\u003C\/sup\u003E, respectively. We have deliberately applied the same methods and assumptions used for the all other diseases to estimate the expected changes in QALY for Spinal Muscular Atrophy Type 1 and Leber Congenital Amaurosis due to RPE65 Mutations even though we could have obtained these numbers directly from ICER reports. By doing so, our price per \u0394QALY calibration will correct for potential biases in our data, and our price estimates will be more realistic.\u003C\/p\u003E\u003Cp id=\u0022p-74\u0022\u003EOur estimated change in QALY, the price per unit change in QALY, and the estimated price of therapy for each disease are shown in \u003Ca id=\u0022xref-table-wrap-7-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T7\u0022\u003ETable 7\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T7\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125788\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125788\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 7:\u003C\/span\u003E \u003Cp id=\u0022p-75\u0022 class=\u0022first-child\u0022\u003EEstimated \u0394QALY, assumed price per \u0394QALY and estimated price of gene therapies per disease. Prices are given to 3 significant figures for display in this table.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-14\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4 Results\u003C\/h2\u003E\u003Cp id=\u0022p-76\u0022\u003EAll the equations are discretized from their continuous form in our computations. When solving integrals using the trapezoidal rule to obtain the \u0394QALY, we use strip widths of 1 year for an age range from 0 to 110 years old, the resolution offered by the life tables. When simulating the number of patients and the cost over time, we use time intervals of 1 month. Our code is implemented on Python 3.6 backed by Numpy, and executed on a single 2.2GHz CPU core. Pseudo-code and further details of computation can be found in Section A8 in the Supplementary Materials.\u003C\/p\u003E\u003Cp id=\u0022p-77\u0022\u003EWe perform 1,000,000 iterations of the simulation to compute the mean number of patients and the total spending. With this number of iterations, one can expect the computed mean to be within 1.89% of the true mean 95% of the time (see Section A7 in the Supplementary Materials). We also report the 5th and 95th percentiles of the computed values as our upper and lower bounds respectively.\u003C\/p\u003E\u003Cp id=\u0022p-78\u0022\u003EIn the following section, we define a \u2018minor\u2019 to be a patient below the age of 18 and an \u2018elderly\u2019 patient to be one who is older than 62 years old. The remainder of the patients are labeled as \u2018adults\u2019.\u003C\/p\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E4.1 Expected Number of Approvals and Patients\u003C\/h3\u003E\u003Cp id=\u0022p-79\u0022\u003EOur simulations indicate that the expected number of gene therapies approved between January 2020 and January 2034 is 18.3, with a 90% confidence interval of [14.0, 23.0] (see \u003Ca id=\u0022xref-fig-8-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F8\u0022\u003EFigure 8\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F8\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F8.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Cumulative number of approvals between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Cumulative number of approvals between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 8:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F8.medium.gif\u0022 width=\u0022440\u0022 height=\u0022128\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 8:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F8.medium.gif\u0022 width=\u0022440\u0022 height=\u0022128\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F8.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 8:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F8.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 8:\u003C\/span\u003E \u003Cp id=\u0022p-80\u0022 class=\u0022first-child\u0022\u003ECumulative number of approvals between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-81\u0022\u003E\u003Ca id=\u0022xref-table-wrap-8-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T8\u0022\u003ETable 8\u003C\/a\u003E shows the annual number of patients over time by age groups. Our simulations expect the number of patients treated to grow from 16,244 in 2020 to 94,696 in 2025 before declining to 65,612 in 2034. The decline can be attributed to the declining stock of existing patients as they are treated, and the fact that we do not consider new development programs launched in the future. The proportions of patients who are minors, adults and elderly are 17.9%, 35.4%, and 46.7% respectively.\u003C\/p\u003E\u003Cdiv id=\u0022T8\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125811\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125811\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125811\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 8:\u003C\/span\u003E \u003Cp id=\u0022p-82\u0022 class=\u0022first-child\u0022\u003EExpected annual number of patients treated by gene therapy between 2020 and 2035, conditioned on the age group and patient type. \u2018Minor\u2019, \u2018adult\u2019 and \u2018elderly\u2019 are defined to be \u2018below the age of 18\u2019, \u2018between the ages of 18 and 62\u2019, and \u2018greater than 62 years old\u2019, respectively.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-83\u0022\u003EWe show the number of patients treated by month in \u003Ca id=\u0022xref-fig-9-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F9\u0022\u003EFigure 9a\u003C\/a\u003E. We can see that our simulations expect the number of patients treated to peak at around 7911 (CI: [3978, 12477]) per month in Jul 2025 before declining to 5424 (CI: [2778, 8350]) by December 2034. The monthly number of existing patients treated exceeds the monthly number of newly-diagnosed patients treated until Sep 2024, when this trend is expected to reverse (see \u003Ca id=\u0022xref-fig-9-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F9\u0022\u003EFigure 9b\u003C\/a\u003E). Only 7% of all patients treated in December 2034 are preexisting patients. Cancer patients are expected to form the biggest group of patients receiving gene therapy treatments, simply due to the number of cancer indications being targeted. We expect the relative proportions of cancer, general disease, and rare disease patients to be 48.0%, 30.0%, and 22.0%, respectively, in December 2034. The cumulative number of patients to be treated is expected to be 1.09 million (CI: [0.595M, 1.66M]) by the end of December 2034 (see \u003Ca id=\u0022xref-fig-9-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F9\u0022\u003EFigure 9c\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F9\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F9.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Number of patients treated between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Number of patients treated between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 9:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F9.medium.gif\u0022 width=\u0022331\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 9:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F9.medium.gif\u0022 width=\u0022331\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F9.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 9:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F9.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 9:\u003C\/span\u003E \u003Cp id=\u0022p-84\u0022 class=\u0022first-child\u0022\u003ENumber of patients treated between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E4.2 Expected Spending\u003C\/h3\u003E\u003Cp id=\u0022p-85\u0022\u003EWe expect an increase in spending up to $2.11 billion per month (CI: [1.01B, 3.88B]) in Apr 2026, before decreasing slowly to a steady-state rate of $1.62 billion (CI: [0.624B, 2.9B]) per month (see \u003Ca id=\u0022xref-fig-10-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F10\u0022\u003EFigure 10a\u003C\/a\u003E). We emphasize that the total spending eventually declines because our simulations analyze a fixed stock of innovations, and do not account for new development programs that may be launched in the future. Treating existing cancer patients initially consumes over 45.6% of the total monthly expenditure, but declines to only 0.99% by December 2034. In contrast, the proportion of spending on new patients in the \u2018general disease\u2019 and \u2018rare disease\u2019 groups will increase from 0.0% and 4.26%, respectively, in Feb 2020 to 21.2% and 46.2% by December 2034. The monthly spending on treating existing patients shall exceed the monthly spending on treating newly diagnosed patients in Nov 2023. The cumulative discounted spending on treating patients with approved gene therapy products is expected to reach $241 billion (CI: [123B, 402B]) by December 2034, 15 years after the start of our simulation.\u003C\/p\u003E\u003Cdiv id=\u0022F10\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F10.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Spending on gene therapy between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Spending on gene therapy between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 10:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F10.medium.gif\u0022 width=\u0022338\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 10:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F10.medium.gif\u0022 width=\u0022338\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F10.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 10:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F10.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 10:\u003C\/span\u003E \u003Cp id=\u0022p-86\u0022 class=\u0022first-child\u0022\u003ESpending on gene therapy between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-87\u0022\u003EIn terms of annual spending on approved gene therapies, we expect that $5.15 billion will be spent in 2020, increasing to $25.3B in 2026 before declining to $21.0B in 2034 (see \u003Ca id=\u0022xref-table-wrap-9-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T9\u0022\u003ETable 9\u003C\/a\u003E). Minors, adults and the elderly will consume 43.2%, 26.0%, and 30.9%, respectively, of the total spending. In the U.S., all elderly people are covered by Medicare. It is also estimated that two in five children and one in seven adults in the U.S. are covered by Medicaid [\u003Ca id=\u0022xref-ref-99-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-99\u0022\u003E99\u003C\/a\u003E]. The remainder of the spending is expected to come from private sources such as employer-provided or private insurance. Using these proportions, we estimate that the expected annual spending by Medicare, Medicaid \u003Csup\u003E\u003Ca id=\u0022xref-fn-7-1\u0022 class=\u0022xref-fn\u0022 href=\u0022#fn-7\u0022\u003E5\u003C\/a\u003E\u003C\/sup\u003E and private sources respectively may reach $8.1, $5.44, and $12.2 billion (see \u003Ca id=\u0022xref-table-wrap-10-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T10\u0022\u003ETable 10\u003C\/a\u003E). We discuss the implications of these estimates in \u003Ca id=\u0022xref-sec-18-1\u0022 class=\u0022xref-sec\u0022 href=\u0022#sec-18\u0022\u003ESection 4.4\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T9\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125786\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125786\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125786\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 9:\u003C\/span\u003E \u003Cp id=\u0022p-88\u0022 class=\u0022first-child\u0022\u003EExpected annual spending on gene therapy between 2020 and 2035, conditioned on the age group and patient type. \u2018Minor\u2019, \u2018adult\u2019 and \u2018elderly\u2019 are defined to be \u2018below the age of 18\u2019, \u2018between the ages of 18 and 62\u2019, and \u2018greater than 62 years old\u2019 respectively. Numbers in billions.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T10\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125814\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125814\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125814\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 10:\u003C\/span\u003E \u003Cp id=\u0022p-89\u0022 class=\u0022first-child\u0022\u003EExpected annual spending on gene therapy between 2020 and 2035 by funding source. Numbers in billions.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-90\u0022\u003EThe total expected increase in QALY over these 15 years is 5.59 million (see \u003Ca id=\u0022xref-fig-11-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F11\u0022\u003EFigure 11\u003C\/a\u003E), which translates to an average increase of 5.12 in QALY per patient. This comes at an average 2020 present value cost of $43,110 per unit change in QALY.\u003C\/p\u003E\u003Cdiv id=\u0022F11\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F11.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Expected \u0026#x394;QALY made possible by gene therapy treatments between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Expected \u0026#x394;QALY made possible by gene therapy treatments between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 11:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F11.medium.gif\u0022 width=\u0022334\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 11:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F11.medium.gif\u0022 width=\u0022334\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F11.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 11:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F11.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 11:\u003C\/span\u003E \u003Cp id=\u0022p-91\u0022 class=\u0022first-child\u0022\u003EExpected \u0394QALY made possible by gene therapy treatments between January 2020 and December 2034, obtained from 1,000,000 simulation runs.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E4.3 Sensitivity Analysis\u003C\/h3\u003E\u003Cp id=\u0022p-92\u0022\u003ETo test the sensitivity of our results to initial conditions, we simulate \u003Cem\u003E\u00b1\u003C\/em\u003E20% changes in the following variables, analyzing their impact on our results.\u003C\/p\u003E\u003Col class=\u0022list-ord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\u003Cp id=\u0022p-93\u0022\u003EThe maximum penetration rate in the ramp function, \u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\u003Cp id=\u0022p-94\u0022\u003EThe time to maximum penetration rate in the ramp function, \u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\u003Cp id=\u0022p-95\u0022\u003EThe amount of QALY gained in each disease\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\u003Cp id=\u0022p-96\u0022\u003EThe price per \u0394QALY\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\u003Cp id=\u0022p-97\u0022\u003EThe phase-3-to-approval probability of success (PoS\u003Csub\u003E3\u003Cem\u003EA\u003C\/em\u003E\u003C\/sub\u003E)\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\u003Cp id=\u0022p-98\u0022\u003EThe number of new patients of each disease\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\u003Cp id=\u0022p-99\u0022\u003EThe number of existing patients of each disease\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-8\u0022\u003E\u003Cp id=\u0022p-100\u0022\u003EThe time from phase 3 to BLA\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-9\u0022\u003E\u003Cp id=\u0022p-101\u0022\u003EThe time from BLA to approval\u003C\/p\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Cp id=\u0022p-102\u0022\u003EFor each of these factors, we consider its impact on the the peak monthly spending and the cumulative spending from January 2020 to December 2034 of patient treatment. We also look at how the variables change the timing of the peak monthly spending.\u003C\/p\u003E\u003Cp id=\u0022p-103\u0022\u003EAs can be seen from \u003Ca id=\u0022xref-fig-12-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F12\u0022\u003EFigure 12\u003C\/a\u003E, the percentage change in the discounted cumulative spending and the maximum monthly spending on treating all patients with gene therapy scale linearly with the percentage change in several variables: the maximum penetration rate (\u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E) and the QALY gained (\u0394QALY), the price per \u0394QALY. Increasing or decreasing the transition probability from phase 3 to approval, or the number of new or existing patients only leads to sublinear increases or decreases in the discounted cumulative spending and the maximum monthly spending. However, changing the time variables, such as the number of days from phase 3 to BLA, from BLA to approval, or the ramp-up period (\u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E), induce a small change in the opposite direction.\u003C\/p\u003E\u003Cdiv id=\u0022F12\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F12.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Tornado charts showing the sensitivity of the variables on the different metrics. The black bars represent the effect of increasing the variable by 20% and the red bars represent the effect of decreasing the variable by 20%.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Tornado charts showing the sensitivity of the variables on the different metrics. The black bars represent the effect of increasing the variable by 20% and the red bars represent the effect of decreasing the variable by 20%.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 12:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F12.medium.gif\u0022 width=\u0022440\u0022 height=\u0022373\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 12:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F12.medium.gif\u0022 width=\u0022440\u0022 height=\u0022373\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F12.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 12:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F12.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 12:\u003C\/span\u003E \u003Cp id=\u0022p-104\u0022 class=\u0022first-child\u0022\u003ETornado charts showing the sensitivity of the variables on the different metrics. The black bars represent the effect of increasing the variable by 20% and the red bars represent the effect of decreasing the variable by 20%.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-105\u0022\u003EIntroducing perturbations of 20% in the probability of success, the number of new patients, the number of days from Phase 3 to BLA or from BLA to approval, or the time to maximum penetration rate in the ramp function (\u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E) will change the date of the peak monthly spending in the same direction as the perturbation, by up to 10 months. Increasing or decreasing the number of existing patients, on the other hand, will cause a shift of up to 4 months in the date of peak spending in the opposite direction. Perturbing the maximum penetration rate (\u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E), the QALY gained (\u0394QALY), and the price per \u0394QALY will not change the date of peak spending.\u003C\/p\u003E\u003Cp id=\u0022p-106\u0022\u003EWe also study the effect of changing the correlation between development programs. Changing the correlation from our assumed value of 0.9 to 0 (i.e., perfectly uncorrelated) increases the mean discounted cumulative spending by 3.4%, from $241 billion to $245 billion. Increasing the correlation to 1.0 instead will decrease the mean discounted cumulative spending by 0.4% to $236 billion.\u003C\/p\u003E\u003Cp id=\u0022p-107\u0022\u003EWe vary the proportion of existing patients seeking treatment in the first year \u2013 which determines the \u003Cem\u003E\u03bb\u003C\/em\u003E parameter in \u003Ca id=\u0022xref-disp-formula-3-1\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-3\u0022\u003EEquation 3\u003C\/a\u003E \u2013 and observe that mean discounted cumulative spending changes by between -32% and +0.08% (see \u003Ca id=\u0022xref-fig-13-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F13\u0022\u003EFigure 13\u003C\/a\u003E). We can expect the results to differ by less than 5% from the baseline if the proportion of existing patients seeking treatments in the first year is between 8% and 45%.\u003C\/p\u003E\u003Cdiv id=\u0022F13\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F13.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Percentage change in the discounted cumulative spending compared to the base-line when the proportion of existing patients seeking treatment in the first year changes.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Percentage change in the discounted cumulative spending compared to the base-line when the proportion of existing patients seeking treatment in the first year changes.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 13:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F13.medium.gif\u0022 width=\u0022440\u0022 height=\u0022152\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 13:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F13.medium.gif\u0022 width=\u0022440\u0022 height=\u0022152\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F13.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 13:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F13.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 13:\u003C\/span\u003E \u003Cp id=\u0022p-108\u0022 class=\u0022first-child\u0022\u003EPercentage change in the discounted cumulative spending compared to the base-line when the proportion of existing patients seeking treatment in the first year changes.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-109\u0022\u003EOur study is independent of the results by Quinn et al. [\u003Ca id=\u0022xref-ref-142-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-142\u0022\u003E142\u003C\/a\u003E], who estimated that 341,775 patients will have been treated with gene therapy by December 2030, and increases by approximately 50,000 per year in the steady state. The authors of this report did not attempt to quantify the cost of providing gene therapy to these patients. In contrast, our simulation expects that about 820,425 patients will be treated by the end of December 2030, with a steady-state increase of around 61,170 per year in the long run.\u003C\/p\u003E\u003Cp id=\u0022p-110\u0022\u003ESome of the differences between our estimates and this other report are due to differences in sample inclusion criteria and the use of different data for patient prevalence and incidence of disease. For example, Quinn et al. [\u003Ca id=\u0022xref-ref-142-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-142\u0022\u003E142\u003C\/a\u003E] considers \u201cdurable\u201d gene therapies under all phases of clinical investigation whereas we consider any therapy with late-stage clinical trial(s). Furthermore, they assume that the \u2018potentially treatable pool in oncology is entirely incident\u2014there is no prevalence\u2019. Another difference arises from our decision to start with the broadest range of patients and then deflate these numbers through the penetration rate, rather than attempting to estimate the prevalence and incidence for each patient segment. If we removed existing oncology patients from our simulation, the cumulative number of patients treated by December 2030 becomes 666,895, approximately 1.95 times the estimate in Quinn et al. [\u003Ca id=\u0022xref-ref-142-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-142\u0022\u003E142\u003C\/a\u003E]. We can obtain similar patient estimates to Quinn et al. [\u003Ca id=\u0022xref-ref-142-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-142\u0022\u003E142\u003C\/a\u003E] simply by reducing our penetration rates by 48.8%, which will lower our estimated cumulative spending on gene therapy between January 2020 and December 2034 to $149 billion.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E4.4 Discussion\u003C\/h3\u003E\u003Cp id=\u0022p-111\u0022\u003EWe estimate that 1.09 million patients are to be treated with gene therapy by the end of December 2034, spending up to $25.3B annually. These estimates are likely to be lower bounds since our simulation employs conservative assumptions about the speed and volume of gene therapy development. Specifically, we consider only late-stage gene therapy development programs, defined as those already in phase 2\/3 or phase 3, and do not account for the possibility that a program in phase 1 or phase 2 may be fast-tracked or granted accelerated approval. We also do not account for any new gene therapies programs being added and approved between 2020 and 2034.\u003C\/p\u003E\u003Cp id=\u0022p-112\u0022\u003EA potential criticism of our approach is that estimating the cost of gene therapies solely based on the change in QALY will overestimate the aggregate spending in the U.S. For example, we do not take into account the potential cost savings to gene therapies due to avoiding multiple costly therapeutic sessions over time based on the current standard of care, or to the recovery of the opportunity cost of caregivers. We have omitted the clinical costs of delivering gene therapy in our analysis, which are often higher than conventional therapeutics due to the need for inpatient hospital care. While there are cases where gene therapy is predicted to provide net cost-savings in treatment after accounting for the direct medical cost (e.g., valoctocogene roxaparvovec for the management of hemophilia A [\u003Ca id=\u0022xref-ref-80-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-80\u0022\u003E80\u003C\/a\u003E]), there is not yet evidence showing that gene therapy will result in net long-term cost savings. In addition, research has shown that new medical technologies generally raise health costs, and that cost-increasing changes in treatments outweigh cost-saving changes the majority of the time [\u003Ca id=\u0022xref-ref-102-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-102\u0022\u003E102\u003C\/a\u003E]. We also do not consider any markup that happens under the prevalent \u2018buy-and-bill\u2019 process in the U.S. These considerations suggest that our approach is indeed conservative, and that our estimates are likely to be lower bounds for realized costs over the next 15 years. Nonetheless, we have taken care to calibrate our price per \u0394QALY using actual prices for approved therapeutics and estimating QALYs for those diseases, thereby allowing us to produce price estimates that closely track past data.\u003C\/p\u003E\u003Cp id=\u0022p-113\u0022\u003EAnother potential criticism is that we fail to consider the possibility that having multiple gene therapies for the same disease may lower the prices of the therapies. However, there is no analogous evidence that the presence of multiple brand-name drugs in the same class lowers the list prices of the drugs [\u003Ca id=\u0022xref-ref-149-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-149\u0022\u003E149\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-114\u0022\u003EBased on our assumptions, the annual spending on gene therapy will average $20.4 billion and may reach $25.3 billion in 2026. This is well above the $819 million threshold recommended by ICER for its annual potential budget impact [\u003Ca id=\u0022xref-ref-93-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-93\u0022\u003E93\u003C\/a\u003E]. The cumulative spending on all future gene therapies from from January 2020 to January 2034 will be approximately $306 billion, or $241 billion when discounted at a cost of capital of 3% per annum over the next 15 years. We estimate the cost of gene therapy to average $43,110 per unit QALY, several times the average annual expenditure of $16,346 for American cancer patients between 2010 and 2014 [\u003Ca id=\u0022xref-ref-138-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-138\u0022\u003E138\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-115\u0022\u003EHowever, when viewed from the broader perspective of aggregate U.S. spending, these figures seem less daunting. In 2018, the U.S. tax revenue was $3.33 trillion, of which individual income tax and payroll tax revenues were $1.68 and $1.17 trillion, respectively [\u003Ca id=\u0022xref-ref-136-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-136\u0022\u003E136\u003C\/a\u003E]. If the average spending of $20.4 billion were to be fully funded through income and payroll taxes, an increase of 0.612% would cover the expense. From a purely budgetary perspective, universal access to gene therapy should be feasible if taxpayers are willing to pay for it. This is probably the simplest and most direct way to provide access to gene therapy to all Americans, though it may not be politically feasible.\u003C\/p\u003E\u003Cp id=\u0022p-116\u0022\u003ESince all elderly patients are covered by Medicare, we estimate that the program would need to increase its annual budget by up to $7.89 billion, or 1.1% of its 2018 spending of\u003C\/p\u003E\u003Cp id=\u0022p-117\u0022\u003E$750.2 billion [\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E]. Funding this increase would require either an increase in payroll taxes or a reduction in other expenditures.\u003C\/p\u003E\u003Cp id=\u0022p-118\u0022\u003EWe estimate that annual gene therapy spending by Medicaid may reach $5.44 billion. This is approximately 0.9% of its 2018 spending of $597.4 billion [\u003Ca id=\u0022xref-ref-19-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E]. Since Medicaid must be provided to all eligible Americans without any preset cap, managing this increase will require either raising funds from state and federal governments to pay for these additional costs, or cutting benefits.\u003C\/p\u003E\u003Cp id=\u0022p-119\u0022\u003EAnnual spending by minors and adults who are ineligible for Medicare or Medicaid\u2014and therefore must rely on private insurers\u2014is predicted to reach $12.2 billion. This spending poses a significant challenge for insurers and companies, who face annual budgets and competing priorities. In order to manage spending, many insurance policies might choose not to cover spending on gene therapy, or impose very restrictive policies to limit the number of potential patients who might be treated [\u003Ca id=\u0022xref-ref-156-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-156\u0022\u003E156\u003C\/a\u003E]. Many private insurers are already warning they may not be able or willing to absorb the additional spending should a greater number of people become eligible for expensive gene therapy treatments once new ones reach the market [\u003Ca id=\u0022xref-ref-159-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-159\u0022\u003E159\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-120\u0022\u003EMany novel methods to finance gene therapy treatments through the existing healthcare infrastructure have been proposed, such as outcome-based payments, whereby the manufacturers would be paid only if the patients achieve predefined outcomes after treatment [\u003Ca id=\u0022xref-ref-72-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-72\u0022\u003E72\u003C\/a\u003E]. We note that both Zolgensma and Luxturna have offered outcome-based payment methods to payers. There have also been proposals to allow mortgage-like payments, and even performance-based annuity payments, as ways to finance gene therapy treatments [\u003Ca id=\u0022xref-ref-133-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-133\u0022\u003E133\u003C\/a\u003E]. In September 2019, Cigna, one of the largest U.S. health insurance companies, announced a program called Embarc Benefit Protection in which employers, health plans, and unions pay a monthly per-member premium that provides members with access to the two FDA-approved gene therapies, Luxturna and Zolgensma, at no out-of-pocket costs to them if their physicians authorize treatment. At the time of writing, Luxturna is not provided under\u003C\/p\u003E\u003Cp id=\u0022p-121\u0022\u003EEmbarc Benefit Protection, and it is unclear if the program is in effect. Cigna hopes to keep the monthly cost of the program to below $1 per member [\u003Ca id=\u0022xref-ref-164-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-164\u0022\u003E164\u003C\/a\u003E], but if our simulations are accurate, this will be financially infeasible.\u003C\/p\u003E\u003Cp id=\u0022p-122\u0022\u003EA more ambitious proposal involves creating a national and possibly international gene therapy reinsurance company that performs a similar function to Embarc, but which serves a large number of primary health insurance providers. By allowing multiple primary insurers to cede the specific risk of gene therapy patients to the reinsurer, these risks can be diversified over a much larger pool members, lowering the cost of capital. The capital required for such a reinsurer can be raised through securitization techniques as described in [\u003Ca id=\u0022xref-ref-133-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-133\u0022\u003E133\u003C\/a\u003E], who simulated such a structure, and concluded that the returns to investors would be quite attractive under a broad range of assumptions. However, their simulations were not specifically calibrated for gene therapy, hence our framework may provide a useful complement to their analysis.\u003C\/p\u003E\u003Cp id=\u0022p-123\u0022\u003EAlso, it may be more cost-effective for the reinsurer to assume the responsibility of delivering the gene therapies it reinsures through nationally distributed Centers of Excellence (CoEs). This may seem too far afield for a reinsurance company, but the ability to have direct control over the quality of delivery, and to be able to collect data on the performance of these therapies over time, are two compelling reasons for the reinsurer to take this on. The data collected from these centers will be critical, not only for assessing the actuarial risk of reinsurance, but also for implementing performance-related contractual agreements, e.g., if a gene therapy ceases to be effective, then any remaining payments for the therapy will be cancelled.\u003C\/p\u003E\u003Cp id=\u0022p-124\u0022\u003EAn additional benefit of a single reinsurer to manage the risk and responsibility of delivering gene therapy is the ability of that reinsurer to avoid the adverse selection problem that often plagues individual insurers [\u003Ca id=\u0022xref-ref-71-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-71\u0022\u003E71\u003C\/a\u003E]. This problem arises when some insurers are willing to pay for gene therapy treatments while others are not, leading patients who require gene therapies to enroll en masse with those insurers providing coverage. Since these policies will likely have higher premiums to cover the high cost of gene therapy, patients have an incentive to leave the policy after receiving the treatment, leaving the insurers to pay the remaining cost without being able to recover the expenses. If a single reinsurer can aggregate this risk across a large pool of gene therapy patients and coordinate payouts across all the insurers, this adverse selection problem can be greatly mitigated, or altogether avoided. The viability of such a reinsurance vehicle would depend critically on the various parameters of the modules in our simulation, as well as the ability to engage with the largest health insurer of all, the U.S. government.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-19\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E5 Conclusion\u003C\/h2\u003E\u003Cp id=\u0022p-125\u0022\u003EIn this paper, we estimate the number of patients who will be treated by gene therapy between January 2020 and December 2034 using various data sources. We also develop a mathematical model to estimate the cost of these gene therapies, and calibrated the model to yield realistic cost estimates. It is our hope that this study, and our estimates of the potential financial impact of gene therapy in the U.S., will clarify some of the unknowns surrounding the impact of this new class of treatment, and allow policymakers, healthcare providers, insurance companies and patients alike to make more informed financial decisions about the future of this important therapeutic class.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-20\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-126\u0022\u003EAll data used in the manuscript are either commercial databases licensed by our respective universities or publicly available data. We intend to make our software available with an open-source license.\u003C\/p\u003E\u003Cp id=\u0022p-127\u0022\u003E\n\u003Ca href=\u0022https:\/\/projectalpha.mit.edu\u0022\u003Ehttps:\/\/projectalpha.mit.edu\u003C\/a\u003E\n\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-21\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EConflicts of Interest Disclosure\u003C\/h2\u003E\u003Cp id=\u0022p-128\u0022\u003EC.W., D.L., and N.W. report no conflicts.\u003C\/p\u003E\u003Cp id=\u0022p-129\u0022\u003ER.M.C. has no conflicts of interest to declare. Her research is funded by grants from the American Cancer Society, the National Cancer Institute, the Leukemia and Lymphoma Society and Arnold Ventures. None of these granting agencies funded her effort on this work.\u003C\/p\u003E\u003Cp id=\u0022p-130\u0022\u003ER.M.C. was also a special economic consultant to the US Food and Drug Administration\u2019s Office of Generic Drugs and is currently a voting committee member of ICER. None of these organizations had any role in the completion of this project, nor R.M.C.\u2019s effort on this project.\u003C\/p\u003E\u003Cp id=\u0022p-131\u0022\u003EJ.G. reports no conflicts. J.G. is a consultant for both the insurer Aetna, Inc and for the biotech company Sarepta, Inc. During the most recent 6 month period JG has received compensation from Aetna, MacMillan publishing, and Access Health, International.\u003C\/p\u003E\u003Cp id=\u0022p-132\u0022\u003EA.L. reports personal investments in private biotech companies, biotech venture capital funds, and mutual funds. A.L. is a co-founder and partner of QLS Advisors, a healthcare analytics and consulting company; an advisor to BrightEdge Ventures; a director of BridgeBio Pharma, Roivant Sciences, and Annual Reviews; chairman emeritus and senior advisor to AlphaSimplex Group; and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH\u2019s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. During the most recent six-year period, A.L. has received speaking\/consulting fees, honoraria, or other forms of compensation from: AIG, AlphaSimplex Group, BIS, BridgeBio Pharma, Citigroup, Chicago Mercantile Exchange, Financial Times, FONDS Professionell, Harvard University, IMF, National Bank of Belgium, Q Group, Roivant Sciences, Scotia Bank, State Street Bank, University of Chicago, and Yale University.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-22\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA1 Current Gene Therapy Clinical Trials\u003C\/h2\u003E\u003Cp id=\u0022p-133\u0022\u003EAs mentioned in the main paper, we list the clinical trials that are used in this study in the following table.\u003C\/p\u003E\u003Cdiv id=\u0022T11\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125808\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125808\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable A1:\u003C\/span\u003E \u003Cp id=\u0022p-134\u0022 class=\u0022first-child\u0022\u003EList of clinical trials used in this study. \u2018TT\u2019 and \u2018CT\u2019 indicates \u2018TrialTrove\u2019 and \u2018\u003Cem\u003Eclinicaltrials\u003C\/em\u003E.\u003Cem\u003Egov\u003C\/em\u003E \u2019 respectively.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-23\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA2 Disease-to-Therapeutic Area Mapping\u003C\/h2\u003E\u003Cp id=\u0022p-135\u0022\u003EAs mentioned in the main paper, we show how the diseases are related to the therapeutic areas in the table below.\u003C\/p\u003E\u003Cdiv id=\u0022T12\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125783\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125783\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable A2:\u003C\/span\u003E \u003Cp id=\u0022p-136\u0022 class=\u0022first-child\u0022\u003EDiseases with ongoing gene therapy trials and their associated therapeutic areas.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-24\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA3 Patient Population Estimation\u003C\/h2\u003E\u003Cp id=\u0022p-137\u0022\u003EWe source the patient prevalence and incidence of the diseases from different sources. When necessary, we compute the prevalence from the incidence using \u003Ca id=\u0022xref-disp-formula-1-4\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-1\u0022\u003EEquation 1\u003C\/a\u003E, or vice versa, using \u003Ca id=\u0022xref-disp-formula-2-3\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-2\u0022\u003EEquation 2\u003C\/a\u003E. Our results are shown in \u003Ca id=\u0022xref-table-wrap-13-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T13\u0022\u003ETable A3\u003C\/a\u003E. These numbers do not reflect the adjustments we make to NSC lung cancer, prostrate cancer and spinal muscular atrophy in order to minimize overlapping patient groups.\u003C\/p\u003E\u003Cdiv id=\u0022T13\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125774\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125774\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable A3:\u003C\/span\u003E \u003Cp id=\u0022p-138\u0022 class=\u0022first-child\u0022\u003ENumber of current patients and annual new patients for each disease. An asterisk (*) indicates that either the prevalence is computed from the incidence using \u003Ca id=\u0022xref-disp-formula-1-5\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-1\u0022\u003EEquation 1\u003C\/a\u003E, or vice versa, using \u003Ca id=\u0022xref-disp-formula-2-4\u0022 class=\u0022xref-disp-formula\u0022 href=\u0022#disp-formula-2\u0022\u003EEquation 2\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-25\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA4 Calibration of Survival Functions \u003Cem\u003ED\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ealt\u003C\/em\u003E\u003C\/sub\u003E(\u003Cem\u003Ex\u003C\/em\u003E \u2212 \u003Cem\u003Ea\u003C\/em\u003E)\u003C\/h2\u003E\u003Cp id=\u0022p-139\u0022\u003EWe source either the survival or mortality rate from literature and use them to compute \u003Cem\u003E\u03bb\u003C\/em\u003E, the time parameter in the exponential survival function. We show our result in the table below.\u003C\/p\u003E\u003Cdiv id=\u0022T14\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125801\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125801\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable A4:\u003C\/span\u003E \u003Cp id=\u0022p-140\u0022 class=\u0022first-child\u0022\u003EList of survival rate or mortality rate and \u003Cem\u003E\u03bb\u003C\/em\u003E, for each disease. An asterisk (*) under \u003Cem\u003E\u03bb\u003C\/em\u003E denotes that the disease does not affect mortality directly.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-26\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA5 Calibration of Age Distribution \u003Cem\u003EA\u003C\/em\u003E(\u003Cem\u003Ex\u003C\/em\u003E)\u003C\/h2\u003E\u003Cp id=\u0022p-141\u0022\u003EAs mentioned in the main paper, our optimization program produces triangular age distributions that conforms to data, have wider support compared to fitting uniform distributions and, avoids sharp changes in the probability density. We illustrate some examples that compare triangle distributions with the uniform distributions with the same average age.\u003C\/p\u003E\u003Cdiv id=\u0022F14\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F14.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Age distributions given various mean ages, \u0026#x3BC;age. The red triangles represent the solutions obtained by our optimization program, while the blue rectangles represent the solutions given by an uniform distribution. The distributions from the optimization program have a wider base of support and avoid sharp changes in density.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Age distributions given various mean ages, \u0026lt;em\u0026gt;\u0026#x3BC;\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;age\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;. The red triangles represent the solutions obtained by our optimization program, while the blue rectangles represent the solutions given by an uniform distribution. The distributions from the optimization program have a wider base of support and avoid sharp changes in density.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A1:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F14.medium.gif\u0022 width=\u0022396\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A1:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F14.medium.gif\u0022 width=\u0022396\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F14.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F14.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A1:\u003C\/span\u003E \u003Cp id=\u0022p-142\u0022 class=\u0022first-child\u0022\u003EAge distributions given various mean ages, \u003Cem\u003E\u03bc\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Eage\u003C\/em\u003E\u003C\/sub\u003E. The red triangles represent the solutions obtained by our optimization program, while the blue rectangles represent the solutions given by an uniform distribution. The distributions from the optimization program have a wider base of support and avoid sharp changes in density.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-27\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA6 Quality of Life Estimation\u003C\/h2\u003E\u003Cp id=\u0022p-143\u0022\u003EThe results of our literature search and estimation for the change in QoL for each disease is shown in the table below.\u003C\/p\u003E\u003Cdiv id=\u0022T15\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/125803\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/125803\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/125803\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable A5:\u003C\/span\u003E \u003Cp id=\u0022p-144\u0022 class=\u0022first-child\u0022\u003ETable of disease scores (\u003Cem\u003E\u03b6\u003C\/em\u003E), estimated quality of life values before treatment \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-7\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T15\/embed\/inline-graphic-7.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T15\/embed\/inline-graphic-7.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E, after treatment \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-8\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T15\/embed\/inline-graphic-8.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/T15\/embed\/inline-graphic-8.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E, and the change in quality of life (\u0394QoL). Asterisks (*) indicate that the values are interpolated. Cancers are not included, as we assume that the gains in survival dominate the gains in QoL.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-28\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA7 Simulation Convergence Criteria\u003C\/h2\u003E\u003Cp id=\u0022p-145\u0022\u003ELet \u003Cem\u003EX\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ek\u003C\/em\u003E\u003C\/sub\u003E be the results of the \u003Cem\u003Ek\u003C\/em\u003E-th simulation. \u003Cem\u003EX\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ek\u003C\/em\u003E\u003C\/sub\u003E has a true mean of \u003Cem\u003E\u03bc\u003C\/em\u003E and variance \u003Cem\u003E\u03c3\u003C\/em\u003E\u003Csup\u003E2\u003C\/sup\u003E. Let the mean of the Monte Carlo simulations over \u003Cem\u003En\u003C\/em\u003E runs be \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-9\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-9.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-9.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E. Then, by Linde-berg\u2013L\u00e9vy\u2019s Central Limit Theorem, \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-10\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-10.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-10.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E converges in distribution to a normal distribution with mean \u003Cem\u003E\u03bc\u003C\/em\u003E and variance of \u003Cem\u003En\u03c3\u003C\/em\u003E\u003Csup\u003E2\u003C\/sup\u003E. The 95 percent confidence interval for \u003Cem\u003E\u03bc\u003C\/em\u003E is given by:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-22\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-74.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/graphic-74.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\nwhere \u003Cem\u003Es\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003En\u003C\/em\u003E\u003C\/sub\u003E is the sample variance of {\u003Cem\u003EX\u003C\/em\u003E\u003Csub\u003E1\u003C\/sub\u003E,, \u003Cem\u003EX\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003En\u003C\/em\u003E\u003C\/sub\u003E}.\u003C\/p\u003E\u003Cp id=\u0022p-146\u0022\u003ESince we are using 1-by-T vectors, we investigated the error in our simulation by dividing the half-range of the confidence interval in each time-step by \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-11\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-11.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/embed\/inline-graphic-11.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E before taking the maximum across the time series. As can be seen from \u003Ca id=\u0022xref-fig-15-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F15\u0022\u003EFigure A2\u003C\/a\u003E, we should expect the simulated mean to be within 1.89% of the true mean 95% of the time with 1,000,000 iterations.\u003C\/p\u003E\u003Cdiv id=\u0022F15\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Plot of  against the number of iterations of simulations of the cost.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Plot of \u0026lt;sup\/\u0026gt; against the number of iterations of simulations of the cost.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A2:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15.medium.gif\u0022 width=\u0022440\u0022 height=\u0022200\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A2:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15.medium.gif\u0022 width=\u0022440\u0022 height=\u0022200\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A2:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A2:\u003C\/span\u003E \u003Cp id=\u0022p-147\u0022 class=\u0022first-child\u0022\u003EPlot of \u003Csup\u003E\u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-12\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15\/embed\/inline-graphic-12.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F15\/embed\/inline-graphic-12.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/sup\u003E against the number of iterations of simulations of the cost.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-29\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA8 Pseudo-Code and Implementation Details\u003C\/h2\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-30\u0022\u003E\u003Ch3\u003EPseudo-code\u003C\/h3\u003E\u003Cp id=\u0022p-148\u0022\u003EWe perform a Monte Carlo simulation to determine the total number of patients undergoing gene therapy and the cost of these gene therapies at specific points in time. The sequence of computations for each iteration of the simulation is detailed in \u003Ca id=\u0022xref-statement-1-1\u0022 class=\u0022xref-statement\u0022 href=\u0022#statement-1\u0022\u003EAlgorithm 1\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022statement-1\u0022 class=\u0022statement\u0022\u003E\u003Cspan class=\u0022statement-label\u0022\u003EAlgorithm 1:\u003C\/span\u003E\u003Ch3\u003EPseudocode for one iteration of the simulation.\u003C\/h3\u003E\u003Cdiv id=\u0022F16\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F16.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F16.medium.gif\u0022 width=\u0022440\u0022 height=\u0022294\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F16.medium.gif\u0022 width=\u0022440\u0022 height=\u0022294\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F16.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure16\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F16.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-149\u0022\u003E\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-31\u0022\u003E\u003Ch3\u003EImplementation\u003C\/h3\u003E\u003Cp id=\u0022p-150\u0022\u003EAll the equations are discretized for computation from their continuous forms. When solving the integrals using the trapezoidal rule to obtain \u0394QALY, we use strip widths of 1 year across a range from 0 to 110 years old, the resolution offered by the life tables. When simulating the number of patients and the cost over time, we use steps of 1 month.\u003C\/p\u003E\u003Cp id=\u0022p-151\u0022\u003EOur codes are implemented on Python 3.6 backed by Numpy. Our vectorized implementation averages 6.120ms per iteration over 1,000,000 runs on a single thread of an Intel Xeon Gold 5120, clocked at 2.20GHz with 20GB of RAM. We attempted to use PyTorch to speed up the computations using a GPU, but it ran more slowly than a single-threaded CPU. We determined this took place for two reasons. First, generating random numbers must be sequential, since PyTorch delegates it solely to the CPU, which limits the amount of parallelization that can be achieved, as dictated by Amdahl\u2019s law. Second, because our computations require a large amount of data from different sources, they must be batched due to the GPU\u2019s limited RAM. The constant movement of data through the PCIe bridge, however, turns out to be a massive bottleneck to the overall speed.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-32\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EA9 Visualization of the Cost over Time\u003C\/h2\u003E\u003Cp id=\u0022p-152\u0022\u003EIn this section, we visualize how the monthly cost of treating patients with gene therapy will be affected by changes to the variables. The results are summarized in the tornado chart presented in the main paper.\u003C\/p\u003E\u003Cdiv id=\u0022F17\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F17.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the time from phase 3 to BLA.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the time from phase 3 to BLA.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A3:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F17.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A3:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F17.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F17.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A3:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F17.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A3:\u003C\/span\u003E \u003Cp id=\u0022p-153\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in the time from phase 3 to BLA.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F18\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F18.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the time from BLA to approval.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the time from BLA to approval.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A4:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F18.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A4:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F18.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F18.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A4:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F18.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A4:\u003C\/span\u003E \u003Cp id=\u0022p-154\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in the time from BLA to approval.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F19\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F19.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a\u0026#xB1;20% change in the number of existing patients.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a\u0026#xB1;20% change in the number of existing patients.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A5:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F19.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A5:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F19.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F19.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A5:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F19.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A5:\u003C\/span\u003E \u003Cp id=\u0022p-155\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a\u00b120% change in the number of existing patients.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F20\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F20.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a 20% change in the number of new patients.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a 20% change in the number of new patients.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A6:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F20.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A6:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F20.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F20.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A6:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F20.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A6:\u003C\/span\u003E \u003Cp id=\u0022p-156\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a 20% change in the number of new patients.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F21\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F21.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the PoS3A.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the PoS\u0026lt;sub\u0026gt;3\u0026lt;em\u0026gt;A\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A7:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F21.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A7:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F21.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F21.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A7:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F21.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A7:\u003C\/span\u003E \u003Cp id=\u0022p-157\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in the PoS\u003Csub\u003E3\u003Cem\u003EA\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F22\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F22.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in \u0026#x394;QALY gained.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in \u0026#x394;QALY gained.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A8:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F22.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A8:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F22.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F22.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A8:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F22.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A8:\u003C\/span\u003E \u003Cp id=\u0022p-158\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in \u0394QALY gained.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F23\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F23.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the cost per \u0026#x394;QALY.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in the cost per \u0026#x394;QALY.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A9:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F23.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A9:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F23.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F23.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A9:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F23.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A9:\u003C\/span\u003E \u003Cp id=\u0022p-159\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in the cost per \u0394QALY.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F24\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F24.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in \u0026#x398;max.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in \u0026#x398;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;max\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A10:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F24.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A10:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F24.medium.gif\u0022 width=\u0022440\u0022 height=\u0022145\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F24.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A10:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F24.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A10:\u003C\/span\u003E \u003Cp id=\u0022p-160\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in \u0398\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F25\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F25.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Impact on monthly cost of treating patients given a \u0026#xB1;20% change in Tmax.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-591077293\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Impact on monthly cost of treating patients given a \u0026#xB1;20% change in \u0026lt;em\u0026gt;T\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;max\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure A11:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F25.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure A11:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F25.medium.gif\u0022 width=\u0022440\u0022 height=\u0022144\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F25.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure A11:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/10\/31\/2020.10.27.20220871\/F25.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure A11:\u003C\/span\u003E \u003Cp id=\u0022p-161\u0022 class=\u0022first-child\u0022\u003EImpact on monthly cost of treating patients given a \u00b120% change in \u003Cem\u003ET\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Emax\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-1\u0022\u003E\u003Cp id=\u0022p-1\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003E*\u003C\/span\u003E We thank Sarah Antiles and Nora Yang for assisting with the preparation of data. We also thank Jon Campbell, Charles Gerrits, Kathy Gooch, Stacey Kowal, Donald Nichols, Mark Trusheim, Karen Tsai, and Ed Tuttle for helpful comments, and Jayna Cummings for editorial support. The views and opinions expressed in this article are those of the authors only and do not necessarily represent the views and opinions of any other organizations, any of their affiliates or employees, or any of the individuals acknowledged above. Funding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged, but no direct funding was received for this study and no funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript). More detailed conflict of interest disclosures are provided after the Conclusion section of the main text.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-2\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EJEL Codes: I11, I13, I18\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-3\u0022\u003E\u003Cp id=\u0022p-162\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-3-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E1\u003C\/sup\u003E\u003C\/span\u003E Compassionate use, also known as \u2018expanded access\u2019, refers to the administration of investigational treatments outside of the clinical trial to treat patients with serious or immediately life-threatening diseases, or conditions when there are no comparable or satisfactory alternative treatment options.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-4\u0022\u003E\u003Cp id=\u0022p-163\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-4-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E2\u003C\/sup\u003E\u003C\/span\u003E We classify Ewing\u2019s Sarcoma\u2014a rare form of cancer\u2014as a rare disease instead of cancer.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-5\u0022\u003E\u003Cp id=\u0022p-164\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-5-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E3\u003C\/sup\u003E\u003C\/span\u003E It must be noted that several pathways, such as the priority review program, are exceptions to this rule. The assumption of perfect correlation still holds if only one trial is required for regulatory review.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-6\u0022\u003E\u003Cp id=\u0022p-165\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-6-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E4\u003C\/sup\u003E\u003C\/span\u003E ICER provides a range of \u0394QALY estimates corresponding to different age groups. We have considered the distribution of ages to produce a weighted average estimate.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-7\u0022\u003E\u003Cp id=\u0022p-166\u0022\u003E\u003Ca class=\u0022rev-xref\u0022 href=\u0022#xref-fn-7-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E5\u003C\/sup\u003E\u003C\/span\u003E The spending estimates for Medicaid do not take into account the 23.1% drug rebate that it is expected to receive [\u003Ca id=\u0022xref-ref-98-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-98\u0022\u003E98\u003C\/a\u003E].\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn\u0022 id=\u0022fn-8\u0022\u003E\u003Cp id=\u0022p-167\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003E\u003Csup\u003E6\u003C\/sup\u003E\u003C\/span\u003E We are unable to find QoL values for SMA only and assume that they are the same as SMA Type 1.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[1].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EDiffuse large b-cell lymphoma - cancer stat facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[2].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EKey statistics for multiple myeloma\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html\u0022\u003Ehttps:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-29\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[3].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EHigh grade gliomas\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.aboutkidshealth.ca\/Article?contentid=1312\u0026amp;language=English\u0022\u003Ehttps:\/\/www.aboutkidshealth.ca\/Article?contentid=1312\u0026amp;language=English\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[4].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Oral Cavity and Pharynx - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[5].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EHeart Failure\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/dhdsp\/data_statistics\/fact_sheets\/fs_heart_failure.htm\u0022\u003Ehttps:\/\/www.cdc.gov\/dhdsp\/data_statistics\/fact_sheets\/fs_heart_failure.htm\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[6].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAcute Lymphocytic Leukemia - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[7].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAcute Myeloid Leukemia - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[8].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAnaplastic Astrocytoma brain cancer\u003C\/span\u003E. URL \u003Ca href=\u0022http:\/\/www.orbustherapeutics.com\/anaplastic\u0022\u003Ehttp:\/\/www.orbustherapeutics.com\/anaplastic\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[9].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EDiffuse Large B-Cell Lymphoma\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/www.lymphoma.org\/aboutlymphoma\/nhl\/dlbcl\/\u0022\u003Ehttps:\/\/www.lymphoma.org\/aboutlymphoma\/nhl\/dlbcl\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[10].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENon-Hodgkin Lymphoma - Cancer Stat Facts\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[11].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EThalassemia Awareness\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/features\/international-thalassemia\/index.html\u0022\u003Ehttps:\/\/www.cdc.gov\/features\/international-thalassemia\/index.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[12].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Urinary Bladder - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[13].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EKey Statistics for Ewing Tumors\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/www.cancer.org\/cancer\/ewing-tumor\/about\/key-statistics.html\u0022\u003Ehttps:\/\/www.cancer.org\/cancer\/ewing-tumor\/about\/key-statistics.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[14].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.14\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EEwing Sarcoma\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/rarediseases.org\/rare-diseases\/ewing-sarcoma\/\u0022\u003Ehttps:\/\/rarediseases.org\/rare-diseases\/ewing-sarcoma\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[15].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EHepatocellular Carcinoma\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/rarediseases.org\/rare-diseases\/hepatocellular-carcinoma\/\u0022\u003Ehttps:\/\/rarediseases.org\/rare-diseases\/hepatocellular-carcinoma\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[16].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EHodgkin lymphoma - cancer stat facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[17].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMelanoma of the Skin - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/melan.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[18].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Prostate - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[19].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference [19] in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENHE Fact Sheet\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet\u0022\u003Ehttps:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[20].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENIH Research Portfolio Online Reporting Tools (RePORT\u003C\/span\u003E). URL \u003Ca href=\u0022https:\/\/report.nih.gov\/NIHfactsheets\/ViewFactSheet.aspx?csid=109\u0022\u003Ehttps:\/\/report.nih.gov\/NIHfactsheets\/ViewFactSheet.aspx?csid=109\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2019-06-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[21].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Urinary Bladder - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[22].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Oral Cavity and Pharynx - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/oralcav.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[23].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Ovary - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[24].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Pancreas - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[25].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Prostate - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/prost.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[26].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.26\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EDiffuse Large B-Cell Lymphoma - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[27].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.27\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ELeber Hereditary Optic Neuropathy\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/rarediseases.org\/rare-diseases\/leber-hereditary-optic-neuropathy\/\u0022\u003Ehttps:\/\/rarediseases.org\/rare-diseases\/leber-hereditary-optic-neuropathy\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[28].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.28\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMelanoma of the Skin - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/melan.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[29].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.29\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENon-Hodgkin Lymphoma - Cancer Stat Facts\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[30].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.30\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EOrphanet: Mucopolysaccharidosis type\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=581\u0022\u003Ehttps:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Expert=581\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-02-27\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[31].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.31\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESurvival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/detection-diagnosis-staging\/factors-prognosis.html\u0022\u003Ehttps:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/detection-diagnosis-staging\/factors-prognosis.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[32].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.32\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESurvival Rates for Nasopharyngeal Cancer\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/www.cancer.org\/cancer\/nasopharyngeal-cancer\/detection-diagnosis-staging\/survival-rates.html\u0022\u003Ehttps:\/\/www.cancer.org\/cancer\/nasopharyngeal-cancer\/detection-diagnosis-staging\/survival-rates.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[33].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.33\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESynovial Sarcoma\u003C\/span\u003E,. URL \u003Ca href=\u0022https:\/\/www.stjude.org\/disease\/synovial-sarcoma.html\u0022\u003Ehttps:\/\/www.stjude.org\/disease\/synovial-sarcoma.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[34].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.34\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENon-hodgkin lymphoma - cancer stat facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[35].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.35\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Lung and Bronchus - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[36].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.36\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EOvarian Cancer Statistics \u2013 Ovarian Cancer Research Alliance\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/ocrahope.org\/patients\/about-ovarian-cancer\/statistics\/\u0022\u003Ehttps:\/\/ocrahope.org\/patients\/about-ovarian-cancer\/statistics\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[37].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.37\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ERecurrence and Treatment \u2013 Ovarian Cancer Research Alliance\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/ocrahope.org\/patients\/about-ovarian-cancer\/recurrence\/\u0022\u003Ehttps:\/\/ocrahope.org\/patients\/about-ovarian-cancer\/recurrence\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[38].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.38\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Ovary \u2013 Cancer Stat Facts\u003C\/span\u003E.,. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[39].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.39\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer of the Pancreas - Cancer Stat Facts\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html\u0022\u003Ehttps:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[40].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.40\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EPrimary peritoneal cancer: Know the basics\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.curetoday.com\/publications\/cure\/2019\/womens-cancers\/primary-peritoneal-cancer-know-the-basics\u0022\u003Ehttps:\/\/www.curetoday.com\/publications\/cure\/2019\/womens-cancers\/primary-peritoneal-cancer-know-the-basics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[41].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.41\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMultiple Myeloma Prognosis - Multiple Myeloma Survival Rate\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/themmrf.org\/multiple-myeloma\/prognosis\/\u0022\u003Ehttps:\/\/themmrf.org\/multiple-myeloma\/prognosis\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[42].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.42\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAbout SMA\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/smafoundation.org\/about-sma\/\u0022\u003Ehttps:\/\/smafoundation.org\/about-sma\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[43].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.43\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESynovial sarcoma\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/rarediseases.info.nih.gov\/diseases\/7721\/synovial-sarcoma\u0022\u003Ehttps:\/\/rarediseases.info.nih.gov\/diseases\/7721\/synovial-sarcoma\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[44].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.44\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAngina by the Numbers - Mortality, Incidence, Prevalence, and other Angina Statistics., Dec 2009\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.mdmag.com\/medical-news\/angina_statistics\u0022\u003Ehttps:\/\/www.mdmag.com\/medical-news\/angina_statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[45].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.45\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ELung Cancer - Non-Small Cell - Statistics, June 2012\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[46].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.46\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ETreatment of Relapsed or Refractory Multiple Myeloma in the Era of Novel Agents, May 2012\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/touchoncology.com\/treatment-of-relapsed-or-refractory-multiple-myeloma-in-the-era-of-novel-agents\/\u0022\u003Ehttps:\/\/touchoncology.com\/treatment-of-relapsed-or-refractory-multiple-myeloma-in-the-era-of-novel-agents\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-03-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[47].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.47\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFast Facts, Jul 2015\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.hemophilia.org\/About-Us\/Fast-Facts\u0022\u003Ehttps:\/\/www.hemophilia.org\/About-Us\/Fast-Facts\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[48].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.48\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EThe Epidemiology of Lysosomal Storage Disorders | DRG Blog, October 2016\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/decisionresourcesgroup.com\/blog\/epidemiology-lysosomal-storage-disorders\/\u0022\u003Ehttps:\/\/decisionresourcesgroup.com\/blog\/epidemiology-lysosomal-storage-disorders\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[49].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.49\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGlioblastoma and Malignant Astrocytoma, 2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[50].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.50\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECancer Facts \u0026amp; Figures\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E2017\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2017\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[51].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.51\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EBrain tumours., Oct 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancerresearchuk.org\/about-cancer\/brain-tumours\/types\/glioma-adults\u0022\u003Ehttps:\/\/www.cancerresearchuk.org\/about-cancer\/brain-tumours\/types\/glioma-adults\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[52].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.52\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWhat is the mortality rate for heart failure?, Nov 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.medscape.com\/answers\/163062-86190\/what-is-the-mortality-rate-for-heart-failure\u0022\u003Ehttps:\/\/www.medscape.com\/answers\/163062-86190\/what-is-the-mortality-rate-for-heart-failure\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[53].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.53\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ELaryngeal and Hypopharyngeal Cancer - Statistics, Aug 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/laryngeal-and-hypopharyngeal-cancer\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/laryngeal-and-hypopharyngeal-cancer\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[54].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.54\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENasal Cavity and Paranasal Sinus Cancer - Statistics, Feb 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/nasal-cavity-and-paranasal-sinus-cancer\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/nasal-cavity-and-paranasal-sinus-cancer\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[55].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.55\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EOral and Oropharyngeal Cancer - Statistics, Dec 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[56].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.56\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENasopharyngeal cancer: Statistics, January 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/nasopharyngeal-cancer\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/nasopharyngeal-cancer\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[57].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.57\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ELung Cancer - Non-Small Cell - Statistics., Mar 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[58].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.58\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EData \u0026amp; Statistics on Sickle Cell Disease, Oct 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html\u0022\u003Ehttps:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[59].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.59\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EIncidence of Sickle Cell Trait in the US, Oct 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/features\/keyfinding-trait.html\u0022\u003Ehttps:\/\/www.cdc.gov\/ncbddd\/sicklecell\/features\/keyfinding-trait.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[60].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.60\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMultiple myeloma - statistics, Mar 2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-29\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[61].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.61\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EEwing Sarcoma - Childhood and Adolescence - Statistics., Feb 2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cancer.net\/cancer-types\/ewing-sarcoma-childhood-and-adolescence\/statistics\u0022\u003Ehttps:\/\/www.cancer.net\/cancer-types\/ewing-sarcoma-childhood-and-adolescence\/statistics\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[62].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.62\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWhat is the mortality rate for diabetic neuropathy?, Jan 2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.medscape.com\/answers\/1170337-4921\/what-is-the-mortality-rate-for-diabetic-neuropathy\u0022\u003Ehttps:\/\/www.medscape.com\/answers\/1170337-4921\/what-is-the-mortality-rate-for-diabetic-neuropathy\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[63].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-63-1\u0022 title=\u0022View reference [63] in text\u0022 id=\u0022ref-63\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.63\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERosa M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAbrantes-Metz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristopher\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAdams\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlbert D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMetz\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPharmaceutical development phases: a duration analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Pharmaceutical Finance, Economics and Policy\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E19\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E42\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2BPharmaceutical%2BFinance%252C%2BEconomics%2Band%2BPolicy%26rft.volume%253D14%26rft.spage%253D19%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[64].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.64\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESarah\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAcaster\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBinny\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPinder\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EClara\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMukuria\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAmanda Copans. Mapping\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Ethe\u003C\/span\u003E\u003C\/span\u003E EQ-5D \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003Eindex from the cystic fibrosis questionnaire-revised using multiple modelling\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Eapproaches\u003C\/span\u003E\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth and Quality of Life Outcomes\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E33\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2Band%2BQuality%2Bof%2BLife%2BOutcomes%26rft.volume%253D13%26rft.spage%253D33%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[65].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.65\u0022 data-doi=\u002210.1016\/B978-1-4377-1604-7.00089-0\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFrank\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAccurso. 89 - Cystic Fibrosis. In Lee Goldman and Andrew I. Schafer, editors, Goldman\u2019s Cecil Medicine (Twenty Fourth Edition\u003C\/span\u003E), pages \u003Cspan class=\u0022cit-fpage\u0022\u003E544\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E548\u003C\/span\u003E. W.B. Saunders, Philadelphia, twenty fourth edition edition, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E. ISBN 978-1-4377-1604-7.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/B978-1-4377-1604-7.00089-0\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E.\u003C\/span\u003E URL \u003Ca href=\u0022http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9781437716047000890\u0022\u003Ehttp:\/\/www.sciencedirect.com\/science\/article\/pii\/B9781437716047000890\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1016%252FB978-1-4377-1604-7.00089-0%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/B978-1-4377-1604-7.00089-0\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[66].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.66\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMP\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAdam\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHH\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EArdinger\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERA\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPagon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESE\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWallace\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELJH\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBean\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStephens\u003C\/span\u003E,\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAmemiya.\u003C\/span\u003E\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EX-Linked Adrenoleukodystrophy\u2013GeneReviews\u00ae\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[67].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-67-1\u0022 title=\u0022View reference [67] in text\u0022 id=\u0022ref-67\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.67\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMichelle Andrews\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EStaggering prices slow insurers\u2019 coverage of car-t cancer therapy, Jul 2018\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/khn.org\/news\/staggering-prices-slow-insurers-coverage-of-car-t-cancer-therapy\/\u0022\u003Ehttps:\/\/khn.org\/news\/staggering-prices-slow-insurers-coverage-of-car-t-cancer-therapy\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-28\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[68].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-68-1\u0022 title=\u0022View reference [68] in text\u0022 id=\u0022ref-68\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.68\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u2019connell Ann\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMeeker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAbruzzini\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAnthony\u003C\/span\u003E\u003C\/span\u003E F., \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHamill\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECaitilin\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZakar\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJessica\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EGlobal approaches to drug development: When ex-us clinical data can support US drug approvals\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.iqvia.com\/library\/white-papers\/global-approaches-to-drug-development\u0022\u003Ehttps:\/\/www.iqvia.com\/library\/white-papers\/global-approaches-to-drug-development\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-20\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[69].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.69\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAmerican Diabetes Association. Statistics About Diabetes\u003C\/span\u003E. URL \u003Ca href=\u0022http:\/\/www.diabetes.org\/diabetes-basics\/statistics\/\u0022\u003Ehttp:\/\/www.diabetes.org\/diabetes-basics\/statistics\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[70].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-70-1\u0022 title=\u0022View reference [70] in text\u0022 id=\u0022ref-70\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.70\u0022 data-doi=\u002210.1377\/hlthaff.2011.0585\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid I\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAuerbach\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArthur L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKellermann\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA decade of health care cost growth has wiped out real income gains for an average US family\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth Affairs\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E30\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1630\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1636\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2BAffairs%26rft.stitle%253DHealth%2BAff%2B%2528Millwood%2529%26rft.aulast%253DAuerbach%26rft.auinit1%253DD.%2BI.%26rft.volume%253D30%26rft.issue%253D9%26rft.spage%253D1630%26rft.epage%253D1636%26rft.atitle%253DA%2BDecade%2BOf%2BHealth%2BCare%2BCost%2BGrowth%2BHas%2BWiped%2BOut%2BReal%2BIncome%2BGains%2BFor%2BAn%2BAverage%2BUS%2BFamily%26rft_id%253Dinfo%253Adoi%252F10.1377%252Fhlthaff.2011.0585%26rft_id%253Dinfo%253Apmid%252F21900652%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiaGVhbHRoYWZmIjtzOjU6InJlc2lkIjtzOjk6IjMwLzkvMTYzMCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzMxLzIwMjAuMTAuMjcuMjAyMjA4NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[71].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-71-1\u0022 title=\u0022View reference [71] in text\u0022 id=\u0022ref-71\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.71\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJane F\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBarlow\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMo\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ Russell\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETeagarden.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAre payers ready, willing, and able to provide access to new durable gene therapies?\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EValue in Health\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E642\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E647\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DValue%2Bin%2BHealth%26rft.volume%253D22%26rft.spage%253D642%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[72].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-72-1\u0022 title=\u0022View reference [72] in text\u0022 id=\u0022ref-72\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.72\u0022 data-doi=\u002210.1038\/nbt.3003\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETroyen A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrennan\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJames M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWilson\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe special case of gene therapy pricing\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature biotechnology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E874\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E876\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%2Bbiotechnology%26rft.volume%253D32%26rft.spage%253D874%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnbt.3003%26rft_id%253Dinfo%253Apmid%252F25203033%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/nbt.3003\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25203033\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[73].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.73\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnh L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBui\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETamara B\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHorwich\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGregg C\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFonarow\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEpidemiology and risk profile of heart failure\u003C\/span\u003E, \u003Cspan class=\u0022cit-month\u0022\u003EJan\u003C\/span\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3033496\/\u0022\u003Ehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3033496\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[74].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-74-1\u0022 title=\u0022View reference [74] in text\u0022 id=\u0022ref-74\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.74\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Census Bureau. U.S. Census Bureau QuickFacts: United States, Jan 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045219\u0022\u003Ehttps:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045219\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-22\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[75].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.75\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJohn R\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBurnett\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EFamilial Lipoprotein Lipase Deficiency, Jun 2017\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1308\/\u0022\u003Ehttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1308\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[76].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.76\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJaime\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECaro\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKristen\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMigliaccio-Walle\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKhajak J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EIshak\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIrina\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EProskorovsky\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Cardiovascular Disorders\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E14\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2005\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBMC%2BCardiovascular%2BDisorders%26rft.volume%253D5%26rft.spage%253D14%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[77].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.77\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELiz\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECarroll\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGary\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBenson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJeremy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELambert\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKhadra\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBenmedjahed\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarek\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZak\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EXin Ying\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EReal-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPatient Preference and Adherence\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E941\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPatient%2BPreference%2Band%2BAdherence%26rft.volume%253D13%26rft.spage%253D941%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[78].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-78-1\u0022 title=\u0022View reference [78] in text\u0022 id=\u0022ref-78\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.78\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJames D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChambers\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAri D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPanzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENikoletta M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMargaretos\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPeter J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENeumann\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EVariation in us private health plans\u2019 coverage of orphan drugs\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm J Manag Care\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E508\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E512\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm%2BJ%2BManag%2BCare%26rft.volume%253D25%26rft.spage%253D508%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[79].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.79\u0022 data-doi=\u002210.1016\/j.preteyeres.2010.04.002\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArtur V\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECideciyan\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ELeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EProgress in Retinal and Eye Research\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E398\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E427\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DProgress%2Bin%2Bretinal%2Band%2Beye%2Bresearch%26rft.stitle%253DProg%2BRetin%2BEye%2BRes%26rft.aulast%253DCideciyan%26rft.auinit1%253DA.%2BV.%26rft.volume%253D29%26rft.issue%253D5%26rft.spage%253D398%26rft.epage%253D427%26rft.atitle%253DLeber%2Bcongenital%2Bamaurosis%2Bdue%2Bto%2BRPE65%2Bmutations%2Band%2Bits%2Btreatment%2Bwith%2Bgene%2Btherapy.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.preteyeres.2010.04.002%26rft_id%253Dinfo%253Apmid%252F20399883%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.preteyeres.2010.04.002\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20399883\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000280663800003\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[80].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-80-1\u0022 title=\u0022View reference [80] in text\u0022 id=\u0022ref-80\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.80\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKeziah\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECook\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EShaun P\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EForbes\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKelly\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAdamski\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJanice J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMa\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnita\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChawla\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELouis P Garrison\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJr\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAssessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia a\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Medical Economics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E501\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E512\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2BMedical%2BEconomics%26rft.volume%253D23%26rft.spage%253D501%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[81].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.81\u0022 data-doi=\u002210.1038\/bmt.2015.307\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERF\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECornell\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAA\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKassim\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEvolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBone marrow transplantation\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E51\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E479\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E491\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBone%2Bmarrow%2Btransplantation%26rft.volume%253D51%26rft.spage%253D479%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fbmt.2015.307%26rft_id%253Dinfo%253Apmid%252F26726946%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/bmt.2015.307\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26726946\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[82].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-82-1\u0022 title=\u0022View reference [82] in text\u0022 id=\u0022ref-82\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.82\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EComparative Effectiveness Public Advisory Council\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EICER reports on spinal muscular\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPharmacoEconomics \u0026amp; Outcomes News\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E823\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPharmacoEconomics%2B%2526%2BOutcomes%2BNews%26rft.volume%253D823%26rft.spage%253D1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[83].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.83\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdele\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u2019Amico\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEugenio\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMercuri\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFrancesco D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETiziano\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEnrico\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBertini\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESpinal muscular atrophy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOrphanet journal of rare diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E10\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOrphanet%2Bjournal%2Bof%2Brare%2Bdiseases%26rft.volume%253D6%26rft.spage%253D1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[84].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-84-1\u0022 title=\u0022View reference [84] in text\u0022 id=\u0022ref-84\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.84\u0022 data-doi=\u002210.1016\/j.jhealeco.2016.01.012\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoseph A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDiMasi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHenry G\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGrabowski\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERonald W\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHansen\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInnovation in the pharmaceutical industry: new estimates of r\u0026amp;d costs\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of health economics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E47\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E20\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E33\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bhealth%2Beconomics%26rft.volume%253D47%26rft.spage%253D20%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jhealeco.2016.01.012%26rft_id%253Dinfo%253Apmid%252F26928437%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jhealeco.2016.01.012\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26928437\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[85].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.85\u0022 data-doi=\u002210.1053\/j.tvir.2016.04.001\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnahita\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDua\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECheong J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELee\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEpidemiology of Peripheral Arterial Disease and Critical Limb Ischemia\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETechniques in Vascular and Interventional Radiology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E91\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E95\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1053\/j.tvir.2016.04.001\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTechniques%2Bin%2BVascular%2Band%2BInterventional%2BRadiology%26rft.volume%253D19%26rft.spage%253D91%26rft_id%253Dinfo%253Adoi%252F10.1053%252Fj.tvir.2016.04.001%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1053\/j.tvir.2016.04.001\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[86].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.86\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESteve\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDuff\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMichael S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMafilios\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPrajakta\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBhounsule\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJames T\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHasegawa\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe burden of critical limb ischemia: a review of recent literature\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVascular health and risk management\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E187\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DVascular%2Bhealth%2Band%2Brisk%2Bmanagement%26rft.volume%253D15%26rft.spage%253D187%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[87].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.87\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EXiaojing\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDuolao\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBruce\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHellman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMathieu F\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJanssen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGerben\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBakker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERupert\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECoghlan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAmelia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHursey\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHelen\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMatthews\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWhetstone\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAssessment of Health-Related Quality of Life between People with Parkinson\u2019s Disease and Non-Parkinson\u2019s: Using Data Drawn from the \u2018100 for Parkinson\u2019s\u2019 Smartphone-Based Prospective Study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInternational Journal of Environmental Research and Public Health\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2538\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInternational%2BJournal%2Bof%2BEnvironmental%2BResearch%2Band%2BPublic%2BHealth%26rft.volume%253D15%26rft.spage%253D2538%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[88].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-88-1\u0022 title=\u0022View reference [88] in text\u0022 id=\u0022ref-88\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.88\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EFDA. Expanded access \u2014 information for industry, May 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.fda.gov\/news-events\/expanded-access\/expanded-access-information-industry\u0022\u003Ehttps:\/\/www.fda.gov\/news-events\/expanded-access\/expanded-access-information-industry\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[89].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.89\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAndrea Ferrari and Paola Collini. What is synovial sarcoma? URL\u003C\/span\u003E \u003Ca href=\u0022http:\/\/sarcomahelp.org\/synovial-sarcoma.html\u0022\u003Ehttp:\/\/sarcomahelp.org\/synovial-sarcoma.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[90].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-90-1\u0022 title=\u0022View reference [90] in text\u0022 id=\u0022ref-90\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.90\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Food and Drug Administration. Step 4: Fda drug review, Apr 2018\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.fda.gov\/patients\/drug-development-process\/step-4-fda-drug-review\u0022\u003Ehttps:\/\/www.fda.gov\/patients\/drug-development-process\/step-4-fda-drug-review\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[91].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-91-1\u0022 title=\u0022View reference [91] in text\u0022 id=\u0022ref-91\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.91\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Food and Drug Administration. CFR - Code of Federal Regulations Title\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E, pApr 2019. URL \u003Ca href=\u0022https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.101\u0022\u003Ehttps:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=314.101\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-04\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[92].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-92-1\u0022 title=\u0022View reference [92] in text\u0022 id=\u0022ref-92\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.92\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInstitute for Clinical and Economic Review. Adapted Value Assessment Methods for High-Impact \u201cSingle and Short-Term Therapies\u201d (SSTs), Nov 2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/icer-review.org\/wp-content\/uploads\/2019\/01\/ICER_SST_FinalAdaptations_111219.pdf\u0022\u003Ehttps:\/\/icer-review.org\/wp-content\/uploads\/2019\/01\/ICER_SST_FinalAdaptations_111219.pdf\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[93].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-93-1\u0022 title=\u0022View reference [93] in text\u0022 id=\u0022ref-93\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.93\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInstitute for Clinical and Economic Review. 2020-2023 Value Assessment Frame-work, January\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/icer-review.org\/material\/2020-value-assessment-framework-final-framework\/\u0022\u003Ehttps:\/\/icer-review.org\/material\/2020-value-assessment-framework-final-framework\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[94].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.94\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECentre for Clinical Practice at NICE (UK\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital\u003C\/span\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[95].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.95\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention. Peripheral arterial disease (PAD\u003C\/span\u003E). URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/heartdisease\/PAD.htm\u0022\u003Ehttps:\/\/www.cdc.gov\/heartdisease\/PAD.htm\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[96].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.96\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention. Diabetes Quick Facts, Aug 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cdc.gov\/diabetes\/basics\/quick-facts.html\u0022\u003Ehttps:\/\/www.cdc.gov\/diabetes\/basics\/quick-facts.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[97].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-97-1\u0022 title=\u0022View reference [97] in text\u0022 id=\u0022ref-97\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.97\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMIT Laboratory for Financial Engineering. Estimates of Clinical Trial Probabilities of Success (PoS), Feb 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/projectalpha.mit.edu\/pos\/\u0022\u003Ehttps:\/\/projectalpha.mit.edu\/pos\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[98].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-98-1\u0022 title=\u0022View reference [98] in text\u0022 id=\u0022ref-98\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.98\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Medicare \u0026amp; Medicaid Services. Medicaid drug rebate program, Nov 2018\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/index.html\u0022\u003Ehttps:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/index.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-09-29\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[99].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-99-1\u0022 title=\u0022View reference [99] in text\u0022 id=\u0022ref-99\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.99\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EKaiser Family Foundation. Medicaid state fact sheets, May 2020\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.kff.org\/interactive\/medicaid-state-fact-sheets\/\u0022\u003Ehttps:\/\/www.kff.org\/interactive\/medicaid-state-fact-sheets\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-08-09\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[100].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.100\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMichael L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGanz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESean\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStern\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlex\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELuba\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENalysnyk\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMartin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESelzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlaa\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHamed\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENeal\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWeinreb\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA new framework for evaluating the health impacts of treatment for Gaucher disease type 1\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOrphanet Journal of Rare Diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E38\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOrphanet%2BJournal%2Bof%2BRare%2BDiseases%26rft.volume%253D12%26rft.spage%253D38%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[101].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.101\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKate\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGardner\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAbdel\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDouiri\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEmma\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDrasar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarlene\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAllman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnne\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMwirigi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMoji\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAwogbade\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESwee Lay\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThein\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESurvival in adults with sickle cell disease in a high-income setting\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBlood, The Journal of the American Society of Hematology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E128\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E1436\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1438\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBlood%252C%2BThe%2BJournal%2Bof%2Bthe%2BAmerican%2BSociety%2Bof%2BHematology%26rft.volume%253D128%26rft.spage%253D1436%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[102].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-102-1\u0022 title=\u0022View reference [102] in text\u0022 id=\u0022ref-102\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.102\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnnetine C\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGelijns\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEthan A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHalm\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe diffusion of new technology: Costs and benefits to health care\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn The Changing Economics of Medical Technology. National Academies Press (US)\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E1991\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[103].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.103\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYezaz Ahmed\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGhouri\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIdrees\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMian\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJulie H\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERowe\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EReview of hepatocellular car-cinoma: Epidemiology, etiology, and carcinogenesis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of carcinogenesis\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[104].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-104-1\u0022 title=\u0022View reference [104] in text\u0022 id=\u0022ref-104\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.104\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGuzman Gloria. New data show income increased in 14 states and 10 of the largest metros, Sept 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.census.gov\/library\/stories\/2019\/09\/us-median-household-income-up-in-2018-from-2017.html\u0022\u003Ehttps:\/\/www.census.gov\/library\/stories\/2019\/09\/us-median-household-income-up-in-2018-from-2017.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-27\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[105].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.105\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPegah\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGolabi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESofie\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFazel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMunkhzul\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOtgonsuren\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMehmet\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESayiner\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECameron T\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELock-lear\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZobair M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYounossi\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMedicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E96\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E), \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[106].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.106\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKimberley A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGoldsmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMatthew T\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDyer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPeter M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchofield\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMartin J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBuxton\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELinda D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESharples\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERelationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth and quality of life outcomes\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E96\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2Band%2Bquality%2Bof%2Blife%2Boutcomes%26rft.volume%253D7%26rft.spage%253D96%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[107].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.107\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ELuis Henrique Wolff Gowdak\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPrevalence of refractory angina in clinical practice\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHeart Metabolism\u003C\/abbr\u003E, (\u003Cspan class=\u0022cit-issue\u0022\u003E72\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E9\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E12\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[108].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.108\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EMohit Gupta. Developments in the Management of BCG-Unresponsive NMIBC, Jan 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.renalandurologynews.com\/home\/news\/urology\/bladder-cancer\/developments-in-the-management-of-bcg-unresponsive-nmibc\/\u0022\u003Ehttps:\/\/www.renalandurologynews.com\/home\/news\/urology\/bladder-cancer\/developments-in-the-management-of-bcg-unresponsive-nmibc\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[109].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.109\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristian J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHendriksz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKenneth I\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBerger\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristina\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELampe\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESusanne G\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKircher\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPaul J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOrchard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERebecca\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESouthall\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESarah\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EStephen\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESande\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJeffrey I\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGold\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EHealth-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOrphanet Journal of Rare Diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E119\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOrphanet%2BJournal%2Bof%2BRare%2BDiseases%26rft.volume%253D11%26rft.spage%253D119%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[110].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.110\u0022 data-doi=\u002210.1093\/eurheartj\/eht165\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETimothy D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHenry\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDaniel\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESatran\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJames S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHodges\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERandall K\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJohnson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnil K\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPoulose\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlex R\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECampbell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERoss F\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGarberich\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBradley A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBart\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERachel E\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOlson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECharlene R\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoisjolie\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ELong-term survival in patients with refractory angina\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEuropean heart journal\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E34\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E34\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2683\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2688\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEuropean%2Bheart%2Bjournal%26rft_id%253Dinfo%253Adoi%252F10.1093%252Feurheartj%252Feht165%26rft_id%253Dinfo%253Apmid%252F23671156%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/eurheartj\/eht165\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23671156\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[111].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.111\u0022 data-doi=\u002210.1136\/hrt.2004.057703\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPaul\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHjemdahl\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESven V\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEriksson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EClaes\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHeld\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELennart\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EForslund\u003C\/span\u003E\u003C\/span\u003E, Per N\u00e4sman, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENina\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERehnqvist\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EFavourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in stockholm (apsis)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHeart\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E92\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E177\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E182\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHeart%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fhrt.2004.057703%26rft_id%253Dinfo%253Apmid%252F15951393%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6ODoiOTIvMi8xNzciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMC8xMC8zMS8yMDIwLjEwLjI3LjIwMjIwODcxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[112].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.112\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESarah\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHouben-Wilke\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERudolf A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJoerres\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERobert\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBals\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFrits ME\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFranssen\u003C\/span\u003E\u003C\/span\u003E, Sven Gl\u00e4ser, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERolf\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHolle\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnnika\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKarch\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArmin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKoch\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHelgo\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMagnussen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnne\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EObst\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPeripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences\u2013Comorbidities Network Study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAmerican Journal of Respiratory and Critical Care Medicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E195\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E189\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E197\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAmerican%2BJournal%2Bof%2BRespiratory%2Band%2BCritical%2BCare%2BMedicine%26rft.volume%253D195%26rft.spage%253D189%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[113].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.113\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMohammad\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHoushyari\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFarzaneh\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHajalikhani\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAfshin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERakhsha\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EParastoo\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHajian\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA comparative study of survival rate in high grade glioma tumors being treated by radiotherapy alone versus chemoradiation with nitrosourea\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EGlobal journal of health science\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E33\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DGlobal%2Bjournal%2Bof%2Bhealth%2Bscience%26rft.volume%253D7%26rft.spage%253D33%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[114].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.114\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInserm. Orphanet: Recessive dystrophic epidermolysis bullosa inversa\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB\u0026amp;Expert=79409\u0022\u003Ehttps:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB\u0026amp;Expert=79409\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[115].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-115-1\u0022 title=\u0022View reference [115] in text\u0022 id=\u0022ref-115\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.115\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInstitute for Clinical and Economic Review. Spinraza\u00ae and zolgensma\u00ae for spinal muscular atrophy: effectiveness and value: final evidence report. 2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[116].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-116-1\u0022 title=\u0022View reference [116] in text\u0022 id=\u0022ref-116\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.116\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJonathan P\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJarow\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESteven\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELemery\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKevin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBugin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESean\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKhozin\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERichard\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMoscicki\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EExpanded access of investigational drugs: the experience of the center of drug evalua-tion and research over a 10-year period\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETherapeutic innovation \u0026amp; regulatory science\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E50\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E705\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E709\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTherapeutic%2Binnovation%2B%2526%2Bregulatory%2Bscience%26rft.volume%253D50%26rft.spage%253D705%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[117].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-117-1\u0022 title=\u0022View reference [117] in text\u0022 id=\u0022ref-117\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.117\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETolbert\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJennifer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EOrgera\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKendal\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESinger\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENatalie\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnthony\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDamico\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EKey facts about the uninsured population, Dec 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.kff.org\/uninsured\/issue-brief\/key-facts-about-the-uninsured-population\/\u0022\u003Ehttps:\/\/www.kff.org\/uninsured\/issue-brief\/key-facts-about-the-uninsured-population\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-27\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[118].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.118\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIn Kyung\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJeon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHye Rang\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOn\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESoo-Chan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of life and economic burden in recessive dystrophic epidermolysis bullosa\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Dermatology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E28\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E6\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E14\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnnals%2Bof%2BDermatology%26rft.volume%253D28%26rft.spage%253D6%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[119].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.119\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003Ede Jong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJoep\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHendricksen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKees\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHugh\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJoost\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EHyperthermic In-travesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients, Jan 2018\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/content.iospress.com\/articles\/bladder-cancer\/blc180191\u0022\u003Ehttps:\/\/content.iospress.com\/articles\/bladder-cancer\/blc180191\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[120].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.120\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAshish M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKamat\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarc\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EColombel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDebasish\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESundi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDonald\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELamm\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAndreas\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoehle\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMaurizio\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrausi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERoger\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBuckley\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERaj\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPersad\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPalou\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMark\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESoloway\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EBCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature Reviews Urology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E244\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E255\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%2BReviews%2BUrology%26rft.volume%253D14%26rft.spage%253D244%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[121].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.121\u0022 data-doi=\u002210.1056\/NEJM199204303261804\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEitan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKerem\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoseph\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EReisman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMary\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECorey\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGerard J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECanny\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHenry\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELevison\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPre-diction of mortality in patients with cystic fibrosis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENew England Journal of Medicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E326\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E18\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1187\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1191\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E1992\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.aulast%253DKerem%26rft.auinit1%253DE.%26rft.volume%253D326%26rft.issue%253D18%26rft.spage%253D1187%26rft.epage%253D1191%26rft.atitle%253DPrediction%2Bof%2Bmortality%2Bin%2Bpatients%2Bwith%2Bcystic%2Bfibrosis%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJM199204303261804%26rft_id%253Dinfo%253Apmid%252F1285737%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJM199204303261804\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=1285737\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1992HR00800004\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[122].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.122\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristine G\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKohn\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMatthew W\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EParker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBrendan L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELimone\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECraig I\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EColeman\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EImpact of angina frequency on health utility values of patients with chronic stable angina\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth and quality of life outcomes\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E39\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2Band%2Bquality%2Bof%2Blife%2Boutcomes%26rft.volume%253D12%26rft.spage%253D39%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[123].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.123\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECathy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELally\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECynthia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJones\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWildon\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFarwell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESandra P\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EReyna\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESuzanne F\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECook\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW Dana\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFlanders.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EIndirect estimation of the prevalence of spinal muscular atrophy type i, ii, and iii in the United States\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOrphanet journal of rare diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E175\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOrphanet%2Bjournal%2Bof%2Brare%2Bdiseases%26rft.volume%253D12%26rft.spage%253D175%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[124].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-124-1\u0022 title=\u0022View reference [124] in text\u0022 id=\u0022ref-124\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.124\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EByron L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELam\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EStephen R\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERussell\u003C\/span\u003E\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVoretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness and Value\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[125].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.125\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristine\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELavery\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChris J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHendriksz\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESimon A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJones\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMortality in patients with sanfilippo syndrome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOrphanet journal of rare diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E168\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOrphanet%2Bjournal%2Bof%2Brare%2Bdiseases%26rft.volume%253D12%26rft.spage%253D168%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[126].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-126-1\u0022 title=\u0022View reference [126] in text\u0022 id=\u0022ref-126\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.126\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ERichard Leong. Average U.S. mortgage size hits record-high $354,500 - mba, Mar 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.reuters.com\/article\/us-usa-mortgages\/average-u-s-mortgage-size-hits-record-high-354500-mba-idUSKBN1QU1VA\u0022\u003Ehttps:\/\/www.reuters.com\/article\/us-usa-mortgages\/average-u-s-mortgage-size-hits-record-high-354500-mba-idUSKBN1QU1VA\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[127].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-book no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.127\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIan M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMacDonald\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENatalia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBinczyk\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlina\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERadziwon\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIoannis\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDimopoulos\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-chapter-title\u0022\u003EChoroi-deremia\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EIn Hereditary Chorioretinal Disorders\u003C\/span\u003E, pages \u003Cspan class=\u0022cit-fpage\u0022\u003E99\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E106\u003C\/span\u003E. \u003Cspan class=\u0022cit-publ-name\u0022\u003ESpringer\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[128].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.128\u0022 data-doi=\u002210.1177\/0883073809341669\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAsif\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMahmood\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJay\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBerry\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWenger\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMaria\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEscolar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMagdi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESobeih\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGerald\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERaymond\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFlorian S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEichler\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMetachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of child neurology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E572\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E580\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bchild%2Bneurology%26rft_id%253Dinfo%253Adoi%252F10.1177%252F0883073809341669%26rft_id%253Dinfo%253Apmid%252F20038527%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1177\/0883073809341669\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20038527\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[129].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.129\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMargolis\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED Scot\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMalay\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EOle J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHoffstad\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECharles E\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELeonard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EThomas MaCurdy\u003C\/span\u003E, \u003Cspan class=\u0022cit-name-surname\u0022\u003EKarla\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u00f3pez\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Ede Nava\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYang\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETeresa\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMolina\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKaren L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESiegel\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EIncidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008. In Data Points Publication Series [Internet]\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAgency for Healthcare Research and Quality (US)\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[130].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.130\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMargolis\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED Scot\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMalay\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EOle J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHoffstad\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECharles E\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELeonard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EThomas\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMaCurdy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKarla L\u00f3pez de\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENava\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYang\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETeresa\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMolina\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKaren L\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESiegel\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPrevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIn Data Points Publication Series [Internet]. Agency for Healthcare Research and Quality (US)\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[131].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.131\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBenjamin J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMiller\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECharles F\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELynch\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoseph A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBuckwalter\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EConditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and ewing\u2019s sarcoma\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClinical Orthopaedics and Related Research\u00ae\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E471\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E3398\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E3404\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClinical%2BOrthopaedics%2Band%2BRelated%2BResearch%25AE%26rft.volume%253D471%26rft.spage%253D3398%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[132].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-132-1\u0022 title=\u0022View reference [132] in text\u0022 id=\u0022ref-132\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.132\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJohn\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMiller\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECaroline\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHumer.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENovartis $2 million gene therapy for rare disorder is world\u2019s most expensive drug, May 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.reuters.com\/article\/us-novartis-genetherapy\/novartis-2-million-gene-therapy-for-rare-disorder-is-worlds-most-expensive-drug-idUSKCN1SU1ZP\u0022\u003Ehttps:\/\/www.reuters.com\/article\/us-novartis-genetherapy\/novartis-2-million-gene-therapy-for-rare-disorder-is-worlds-most-expensive-drug-idUSKCN1SU1ZP\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-28\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[133].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-133-1\u0022 title=\u0022View reference [133] in text\u0022 id=\u0022ref-133\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.133\u0022 data-doi=\u002210.1126\/scitranslmed.aad6913\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVahid\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMontazerhodjat\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWeinstock\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAndrew W. Lo. Buying Cures\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Evs\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERenting Health: Financing Healthcare via Consumer Loans\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EScience Translational Medicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E327ps6\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DScience%2BTranslational%2BMedicine%26rft.stitle%253DSci%2BTransl%2BMed%26rft.aulast%253DMontazerhodjat%26rft.auinit1%253DV.%26rft.volume%253D8%26rft.issue%253D327%26rft.spage%253D327ps6%26rft.epage%253D327ps6%26rft.atitle%253DBuying%2Bcures%2Bversus%2Brenting%2Bhealth%253A%2BFinancing%2Bhealth%2Bcare%2Bwith%2Bconsumer%2Bloans%26rft_id%253Dinfo%253Adoi%252F10.1126%252Fscitranslmed.aad6913%26rft_id%253Dinfo%253Apmid%252F26912902%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6InNjaXRyYW5zbWVkIjtzOjU6InJlc2lkIjtzOjEyOiI4LzMyNy8zMjdwczYiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMC8xMC8zMS8yMDIwLjEwLjI3LjIwMjIwODcxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[134].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.134\u0022 data-doi=\u002210.1016\/j.joca.2010.06.001.\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMuraki\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAkune\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOka\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEn-Yo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYoshida\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESaika\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESuzuki\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYoshida\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EIshibashi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETokimura\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociation of radiographic and symptomatic knee osteoarthritis with health-related quality of life in a population-based cohort study in Japan: the ROAD study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOsteoarthritis and Cartilage\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1227\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1234\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOsteoarthritis%2Band%2Bcartilage%2B%252F%2BOARS%252C%2BOsteoarthritis%2BResearch%2BSociety%26rft.stitle%253DOsteoarthritis%2BCartilage%26rft.aulast%253DMuraki%26rft.auinit1%253DS.%26rft.volume%253D18%26rft.issue%253D9%26rft.spage%253D1227%26rft.epage%253D1234%26rft.atitle%253DAssociation%2Bof%2Bradiographic%2Band%2Bsymptomatic%2Bknee%2Bosteoarthritis%2Bwith%2Bhealth-related%2Bquality%2Bof%2Blife%2Bin%2Ba%2Bpopulation-based%2Bcohort%2Bstudy%2Bin%2BJapan%253A%2Bthe%2BROAD%2Bstudy.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.joca.2010.06.001.%26rft_id%253Dinfo%253Apmid%252F20633679%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.joca.2010.06.001.\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20633679\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000282459500015\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[135].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-135-1\u0022 title=\u0022View reference [135] in text\u0022 id=\u0022ref-135\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.135\u0022 data-doi=\u002210.1056\/NEJMp1405158\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENeumann\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECohen\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWeinstein\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EUpdating cost-effectiveness\u2014the curious resilience of the $50,000-per-qaly threshold\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENew England Journal of Medicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E371\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E796\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E797\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/doi.org\/10.1056\/NEJMp1405158\u0022\u003Ehttps:\/\/doi.org\/10.1056\/NEJMp1405158\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.volume%253D371%26rft.spage%253D796%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMp1405158%26rft_id%253Dinfo%253Apmid%252F25162885%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMp1405158\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25162885\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000340819800005\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[136].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-136-1\u0022 title=\u0022View reference [136] in text\u0022 id=\u0022ref-136\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.136\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECongressional Budget Office. The budget and economic outlook: 2019 to\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E2029\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[137].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.137\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EOrphanet. Beta thalassemia major\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=EN\u0026amp;Expert=231214\u0022\u003Ehttps:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=EN\u0026amp;Expert=231214\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-04\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[138].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-138-1\u0022 title=\u0022View reference [138] in text\u0022 id=\u0022ref-138\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.138\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoohyun\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKevin A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELook\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EHealth care expenditure burden of cancer care in the United States\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EINQUIRY: The Journal of Health Care Organization, Provision, and Financing\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E56\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E0046958019880696\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DINQUIRY%253A%2BThe%2BJournal%2Bof%2BHealth%2BCare%2BOrganization%252C%2BProvision%252C%2Band%2BFinancing%26rft.volume%253D56%26rft.spage%253D0046958019880696%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[139].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.139\u0022 data-doi=\u002210.1038\/sj.ejhg.5201044\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERui\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPinto\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECarla\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECaseiro\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EManuela\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELemos\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELurdes\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELopes\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAugusta\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFontes\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHelena\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERibeiro\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEug\u00e9nia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPinto\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EElisabete\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESilva\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESonia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERocha\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAna\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMarcao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPrevalence of lysosomal storage diseases in Portugal\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEuropean Journal of Human Genetics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E (\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E87\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E92\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2004\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEuropean%2Bjournal%2Bof%2Bhuman%2Bgenetics%2B%253A%2B%2BEJHG%26rft.stitle%253DEur%2BJ%2BHum%2BGenet%26rft.aulast%253DPinto%26rft.auinit1%253DR.%26rft.volume%253D12%26rft.issue%253D2%26rft.spage%253D87%26rft.epage%253D92%26rft.atitle%253DPrevalence%2Bof%2Blysosomal%2Bstorage%2Bdiseases%2Bin%2BPortugal.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fsj.ejhg.5201044%26rft_id%253Dinfo%253Apmid%252F14685153%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/sj.ejhg.5201044\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=14685153\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000188397500002\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[140].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.140\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIris\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPlug\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJG\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVan Der Bom\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarjolein\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPeters\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEP\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMauser-Bunschoten\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArja\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDE GOEDE-BOLDER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELily\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHeijnen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECees\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmit\u003C\/span\u003E\u003C\/span\u003E, Jos\u00e9 Willemse, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFR\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERosendaal\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMortality and causes of death in patients with hemophilia, 1992\u20132001: a prospective cohort study 1\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Thrombosis and Haemostasis\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E510\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E516\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2BThrombosis%2Band%2BHaemostasis%26rft.volume%253D4%26rft.spage%253D510%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[141].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.141\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMariano\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EProvencio\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDolores\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EIsla\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAntonio\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u00e1nchez\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBlanca\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECantos\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInoperable stage iii non-small cell lung cancer: Current treatment and role of vinorelbine\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of thoracic disease\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E197\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bthoracic%2Bdisease%26rft.volume%253D3%26rft.spage%253D197%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[142].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-142-1\u0022 title=\u0022View reference [142] in text\u0022 id=\u0022ref-142\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.142\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECasey\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EQuinn\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EColin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYoung\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJonathan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThomas\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMark\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETrusheim\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEstimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EValue in Health\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E621\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E626\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DValue%2Bin%2BHealth%26rft.volume%253D22%26rft.spage%253D621%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[143].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.143\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGerald V\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERaymond\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPatrick\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAubourg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAsif\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPaker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMaria\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEscolar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlain\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFischer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EStephane\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBlanche\u003C\/span\u003E\u003C\/span\u003E, Andr\u00e9 Baruchel, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJean-Hugues\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDalle\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG\u00e9rard\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMichel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVinod\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPrasad\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESurvival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiology of Blood and Marrow Transplantation\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E538\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E548\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiology%2Bof%2BBlood%2Band%2BMarrow%2BTransplantation%26rft.volume%253D25%26rft.spage%253D538%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[144].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.144\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGenetics Home Reference. Retinitis pigmentosa\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/ghr.nlm.nih.gov\/condition\/retinitis-pigmentosa\u0022\u003Ehttps:\/\/ghr.nlm.nih.gov\/condition\/retinitis-pigmentosa\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[145].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.145\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPeter\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EReichardt\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMichael\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELeahy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EXavier Garcia\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Edel Muro\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EStefano\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFerrari\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJavier\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHans\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGelderblom\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJingshu\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArun\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKrishna\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJennifer\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEriksson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EArthur\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStaddon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EQuality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESarcoma\u003C\/abbr\u003E, 2012, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[146].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.146\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJeffrey M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERobbins\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGerald\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStrauss\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDavid\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAron\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJodi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJennifer\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKuba\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYelena\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKaplan\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration?\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of the American Podiatric Medical Association\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E98\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E489\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E493\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bthe%2BAmerican%2BPodiatric%2BMedical%2BAssociation%26rft.volume%253D98%26rft.spage%253D489%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[147].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.147\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESanjoy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERoy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDebarshi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELahiri\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETapas\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMaji\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJaydip\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBiswas\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERecurrent glioblastoma: where we stand\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESouth Asian journal of cancer\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E163\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSouth%2BAsian%2Bjournal%2Bof%2Bcancer%26rft.volume%253D4%26rft.spage%253D163%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[148].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.148\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAlette\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERuarus\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELaurien\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVroomen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERobbert\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPuijk\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHester\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScheffer\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMartijn\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMeijerink\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ELocally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies, Jan 2018\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5789366\/\u0022\u003Ehttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5789366\/\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[149].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-149-1\u0022 title=\u0022View reference [149] in text\u0022 id=\u0022ref-149\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.149\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAmeet\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESarpatwari\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJonathan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDiBello\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarie\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZakarian\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMehdi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENajafzadeh\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAaron S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKesselheim\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECompetition and price among brand-name drugs in the same class: A systematic review of the evidence\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS medicine\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E7\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee1002872\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2Bmedicine%26rft.volume%253D16%26rft.spage%253D1002872e%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[150].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.150\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBjoern\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchwander\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEarly health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth Economics Review\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E27\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2BEconomics%2BReview%26rft.volume%253D4%26rft.spage%253D27%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[151].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.151\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMeysam\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESeyedifar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFarid Abedin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDorkoosh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAmir Ali\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHamidieh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMajid\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENaderi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHossein\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKarami\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMehran\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKarimi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMasoomeh\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFadaiyrayeny\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMasoumeh\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMusavi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESanaz\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESafaei\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMohammad Mahdi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAhmadian-Attari\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EHealth-related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in Iran\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInternational Journal of Hematology-Oncology and Stem Cell Research\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E224\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInternational%2BJournal%2Bof%2BHematology-Oncology%2Band%2BStem%2BCell%2BResearch%26rft.volume%253D10%26rft.spage%253D224%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[152].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.152\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJames\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShearer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EColin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGreen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECarl E\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECounsell\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJohn P\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZajicek\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson\u2019s disease\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Neurology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E259\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E462\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E468\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bneurology%26rft.stitle%253DJ%2BNeurol%26rft.aulast%253DShearer%26rft.auinit1%253DJ.%26rft.volume%253D259%26rft.issue%253D3%26rft.spage%253D462%26rft.epage%253D468%26rft.atitle%253DThe%2Bimpact%2Bof%2Bmotor%2Band%2Bnon%2Bmotor%2Bsymptoms%2Bon%2Bhealth%2Bstate%2Bvalues%2Bin%2Bnewly%2Bdiagnosed%2Bidiopathic%2BParkinson%2527s%2Bdisease.%26rft_id%253Dinfo%253Apmid%252F21818689%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21818689\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[153].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.153\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJayne\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith-Palmer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJay P\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBae\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKristina S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoye\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKirsi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENorrbacka\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBarnaby\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHunt\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWilliam J\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EValentine\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEvaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClinicoEconomics and outcomes research: CEOR\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E559\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClinicoEconomics%2Band%2Boutcomes%2Bresearch%253A%2BCEOR%26rft.volume%253D8%26rft.spage%253D559%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[154].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.154\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESothornwit\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGulapar\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESrisawasdi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAtchara\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESuwannakin\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EApiradee\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESriwijitkamol\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EDecreased health-related quality of life in patients with diabetic foot problems\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E35\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDiabetes%252C%2BMetabolic%2BSyndrome%2Band%2BObesity%253A%2BTargets%2Band%2BTherapy%26rft.volume%253D11%26rft.spage%253D35%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[155].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.155\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003EJ \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERichard\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESteadman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKaren K\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBriggs\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELauren M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMatheny\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHenry B\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEllis\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ETen-year survivorship after knee arthroscopy in patients with kellgren-lawrence grade 3 and grade 4 osteoarthritis of the knee\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArthroscopy: The Journal of Arthroscopic \u0026amp; Related Surgery\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E220\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E225\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DArthroscopy%253A%2BThe%2BJournal%2Bof%2BArthroscopic%2B%2526%2BRelated%2BSurgery%26rft.volume%253D29%26rft.spage%253D220%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[156].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-156-1\u0022 title=\u0022View reference [156] in text\u0022 id=\u0022ref-156\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.156\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESullivan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThomas\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EHow are insurers treating the $2m drug, zolgensma?, Oct 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.policymed.com\/2019\/10\/how-are-insurers-treating-the-2m-drug-zolgensma.html\u0022\u003Ehttps:\/\/www.policymed.com\/2019\/10\/how-are-insurers-treating-the-2m-drug-zolgensma.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-27\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[157].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-157-1\u0022 title=\u0022View reference [157] in text\u0022 id=\u0022ref-157\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.157\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMeg\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETirrell\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA US drugmaker offers to cure rare blindness for $850,000, Jan 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.cnbc.com\/2018\/01\/03\/spark-therapeutics-luxturna-gene-therapy-will-cost-about-850000.html\u0022\u003Ehttps:\/\/www.cnbc.com\/2018\/01\/03\/spark-therapeutics-luxturna-gene-therapy-will-cost-about-850000.html\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-06-28\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[158].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.158\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003ESoili Torm\u00e4lehto, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMika E\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMononen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEmma\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAarnio\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJari PA\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EArokoski\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERami K\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKorhonen\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJanne\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMartikainen\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EHealth-related quality of life in relation to symptomatic and radiographic definitions of knee osteoarthritis: data from Osteoarthritis Initiative (OAI) 4-year follow-up study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHealth and Quality of Life Outcomes\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E154\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHealth%2Band%2BQuality%2Bof%2BLife%2BOutcomes%26rft.volume%253D16%26rft.spage%253D154%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[159].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-159-1\u0022 title=\u0022View reference [159] in text\u0022 id=\u0022ref-159\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.159\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJohn\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETozzi\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEmployers fear squeeze from genetic cures that cost millions, September 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.bloomberg.com\/news\/articles\/2019-09-11\/employers-fear-squeeze-from-genetic-cures-that-cost-millions\u0022\u003Ehttps:\/\/www.bloomberg.com\/news\/articles\/2019-09-11\/employers-fear-squeeze-from-genetic-cures-that-cost-millions\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-04-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[160].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.160\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003Eascular Surgery Unit\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAtherosclerosis obliterans of the lower extremities in thai patients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Med Assoc Thai\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E89\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1612\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E20\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bthe%2BMedical%2BAssociation%2Bof%2BThailand%2B%253D%2BChotmaihet%2Bthangphaet%26rft.stitle%253DJ%2BMed%2BAssoc%2BThai%26rft.aulast%253DMutirangura%26rft.auinit1%253DP.%26rft.volume%253D89%26rft.issue%253D10%26rft.spage%253D1612%26rft.epage%253D1620%26rft.atitle%253DAtherosclerosis%2Bobliterans%2Bof%2Bthe%2Blower%2Bextremities%2Bin%2BThai%2Bpatients.%26rft_id%253Dinfo%253Apmid%252F17128835%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=17128835\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[161].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.161\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Department of Health and Human Services\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ENIH Research Portfolio Online Reporting Tools (RePORT)\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/report.nih.gov\/nihfactsheets\/viewfactsheet.aspx?csid=55\u0022\u003Ehttps:\/\/report.nih.gov\/nihfactsheets\/viewfactsheet.aspx?csid=55\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2019-06-10\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[162].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.162\u0022 data-doi=\u002210.1530\/ERC-17-0336\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBelinda\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Evan Zyl\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDenise\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETang\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENikola A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBowden\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBiomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEndocrine-related cancer\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003ER303\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003ER318\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEndocrine-related%2Bcancer%26rft_id%253Dinfo%253Adoi%252F10.1530%252FERC-17-0336%26rft_id%253Dinfo%253Apmid%252F29487129%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiZXJjIjtzOjU6InJlc2lkIjtzOjk6IjI1LzUvUjMwMyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzMxLzIwMjAuMTAuMjcuMjAyMjA4NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[163].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.163\u0022 data-doi=\u002210.1007\/s00167-005-0621-1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPeter\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVorlat\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGuy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPutzeys\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDominique\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECottenie\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETom\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVan Isacker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENicole\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPouliart\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFrank\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHandelberg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPierre-Paul\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECasteleyn\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFilip\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGheysen\u003C\/span\u003E\u003C\/span\u003E, and Ren\u00e9 Verdonk. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe oxford unicompartmental knee prosthesis: an independent 10-year survival analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EKnee Surgery, Sports Traumatology, Arthroscopy\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E40\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E45\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DKnee%2Bsurgery%252C%2Bsports%2Btraumatology%252C%2Barthroscopy%2B%253A%2B%2Bofficial%2Bjournal%2Bof%2Bthe%2BESSKA%26rft.stitle%253DKnee%2BSurg%2BSports%2BTraumatol%2BArthrosc%26rft.aulast%253DVorlat%26rft.auinit1%253DP.%26rft.volume%253D14%26rft.issue%253D1%26rft.spage%253D40%26rft.epage%253D45%26rft.atitle%253DThe%2BOxford%2Bunicompartmental%2Bknee%2Bprosthesis%253A%2Ban%2Bindependent%2B10-year%2Bsurvival%2Banalysis.%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs00167-005-0621-1%26rft_id%253Dinfo%253Apmid%252F15895294%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1007\/s00167-005-0621-1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=15895294\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000234600900008\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[164].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-164-1\u0022 title=\u0022View reference [164] in text\u0022 id=\u0022ref-164\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.10.27.20220871v1.164\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoseph\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWalker\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnna Wilde\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMathews\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInsurers Pitch New Ways to Pay for Million-Dollar Therapies, Sep 2019\u003C\/span\u003E. URL \u003Ca href=\u0022https:\/\/www.wsj.com\/articles\/insurers-pitch-new-ways-to-pay-for-million-dollar-therapies-11567677600\u0022\u003Ehttps:\/\/www.wsj.com\/articles\/insurers-pitch-new-ways-to-pay-for-million-dollar-therapies-11567677600\u003C\/a\u003E. Accessed: \u003Cspan class=\u0022cit-date-in-citation\u0022\u003E2020-05-04\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[165].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.165\u0022 data-doi=\u002210.1001\/archneurol.2011.2370\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAllison W\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWillis\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMario\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchootman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENathan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKung\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBradley A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEvanoff\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoel S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPerl-mutter\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBrad A\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERacette\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPredictors of survival in patients with parkinson disease\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArchives of neurology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E69\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E601\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E607\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DArchives%2Bof%2BNeurology%26rft.stitle%253DArch%2BNeurol%26rft.volume%253D69%26rft.issue%253D5%26rft.spage%253D601%26rft.epage%253D607%26rft.atitle%253DPredictors%2Bof%2Bsurvival%2Bin%2Bpatients%2Bwith%2BParkinson%2Bdisease.%26rft_id%253Dinfo%253Adoi%252F10.1001%252Farchneurol.2011.2370%26rft_id%253Dinfo%253Apmid%252F22213411%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/archneurol.2011.2370\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22213411\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[166].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-166-1\u0022 title=\u0022View reference [166] in text\u0022 id=\u0022ref-166\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.166\u0022 data-doi=\u002210.1093\/biostatistics\/kxx069\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChi Heem\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKien Wei\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESiah\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAndrew W\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEstimation of clinical trial success rates and related parameters\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiostatistics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E273\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E286\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiostatistics%26rft.volume%253D20%26rft.spage%253D273%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fbiostatistics%252Fkxx069%26rft_id%253Dinfo%253Apmid%252F29394327%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/biostatistics\/kxx069\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=29394327\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[167].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.167\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJing\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYuerong\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJudy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EYang\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHongliang\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJunyi\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZheng\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHe\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESun\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EChronic stable angina is associated with lower health-related quality of life: evidence from Chinese patients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E), \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[168].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.168\u0022 data-doi=\u002210.1007\/BF00400697\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYoung\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoulton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMacleod\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. R. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWilliams\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESonksen\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiabetologia\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E150\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E154\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E1993\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1007\/bf00400697\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDiabetologia%26rft.stitle%253DDiabetologia%26rft.aulast%253DYoung%26rft.auinit1%253DM.%2BJ.%26rft.volume%253D36%26rft.issue%253D2%26rft.spage%253D150%26rft.epage%253D154%26rft.atitle%253DA%2Bmulticentre%2Bstudy%2Bof%2Bthe%2Bprevalence%2Bof%2Bdiabetic%2Bperipheral%2Bneuropathy%2Bin%2Bthe%2BUnited%2BKingdom%2Bhospital%2Bclinic%2Bpopulation.%26rft_id%253Dinfo%253Adoi%252F10.1007%252FBF00400697%26rft_id%253Dinfo%253Apmid%252F8458529%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1007\/BF00400697\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=8458529\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1993KH64700011\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[169].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.169\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EReza\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZamani\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESalman\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKhazaei\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EShahab\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERezaeian\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESurvival analysis and its associated factors of beta thalassemia major in hamadan province\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EIranian journal of medical sciences\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E40\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E233\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DIranian%2Bjournal%2Bof%2Bmedical%2Bsciences%26rft.volume%253D40%26rft.spage%253D233%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[170].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.170\u0022 data-doi=\u002210.1001\/archneur.1995.00540290108025\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKlaus\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZerres\u003C\/span\u003E\u003C\/span\u003E and Sabine Rudnik-Sch\u00f6neborn. \u003Cspan class=\u0022cit-article-title\u0022\u003ENatural history in proximal spinal muscular atrophy: clinical analysis of 445 patients and suggestions for a modification of existing classifications\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArchives of neurology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E52\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E518\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E523\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E1995\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DArchives%2Bof%2BNeurology%26rft.stitle%253DArch%2BNeurol%26rft.aulast%253DZerres%26rft.auinit1%253DK.%26rft.volume%253D52%26rft.issue%253D5%26rft.spage%253D518%26rft.epage%253D523%26rft.atitle%253DNatural%2BHistory%2Bin%2BProximal%2BSpinal%2BMuscular%2BAtrophy%253A%2BClinical%2BAnalysis%2Bof%2B445%2BPatients%2Band%2BSuggestions%2Bfor%2Ba%2BModification%2Bof%2BExisting%2BClassifications%26rft_id%253Dinfo%253Adoi%252F10.1001%252Farchneur.1995.00540290108025%26rft_id%253Dinfo%253Apmid%252F7733848%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/archneur.1995.00540290108025\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=7733848\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F31%2F2020.10.27.20220871.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1995QW84300018\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[171].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-171-1\u0022 title=\u0022View reference [171] in text\u0022 id=\u0022ref-171\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.10.27.20220871v1.171\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAudrey D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJeremy\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPuthumana\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENicholas S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDowning\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENilay D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShah\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHarlan M\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKrumholz\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJoseph S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERoss\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAssessment of clinical trials supporting US food and drug administration approval of novel therapeutic agents, 1995-2017\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Network Open\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee203284\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003Ee203284\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%2BNetwork%2BOpen%26rft.volume%253D3%26rft.spage%253D203284e%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[172].\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.10.27.20220871v1.172\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESantiago\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZuluaga-Sanchez\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMegan\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETeynor\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EChristopher\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKnight\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERobin\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EThomas\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELundqvist\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMats\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEkelund\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAnnabelle\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EForsmark\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAdrian D\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVickers\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAndrew\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELloyd\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPharmacoEconomics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E845\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E865\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPharmacoEconomics%26rft.volume%253D37%26rft.spage%253D845%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}